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Chapter 1
General Introduction
9Introduction
Acute lymphoblastic leukemia
Acute lymphoblastic leukemia (ALL) is the most frequently occurring pediatric cancer, 
representing 120 new cases yearly in the Netherlands.1 The peak incidence of this disease 
is between the ages of two and fi ve years. In normal hematopoiesis the self-renewing 
hematopoietic stem cells in the bone marrow develop towards all diff erent mature 
blood cell types (Figure 1). ALL is characterized by the presence of rapidly proliferating, 
monoclonal lymphoid progenitor cells. The uncontrolled expansion of leukemic cells 
leads to a compromised production of healthy mature blood cells, resulting in depletion 
of erythrocytes, platelets, and functional white blood cells.2 
In children, ALL originating from immature B-cells is far more common (~85%) than 
ALL originating from immature T lymphocytes (~15%).3
Increased ALL survival
During the last decades, survival rates of childhood ALL have increased considerably 
(Figure 2) to a current overall fi ve-year event-free survival of more than 85%.4-6 
This increased survival is the result of the development of eff ective combination 
chemotherapy, optimized stratifi cation of therapy, as well as optimized supportive care 
regimens. As outcome of ALL in children is good, attention is more and more focused on 
recognizing determinants of direct and late side eff ects in order to avoid unnecessary 
therapy-related morbidity and mortality.
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Figure 1. Normal hematopoiesis.
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Treatment of ALL typically consists of an induction, consolidation, intensifi cation, and 
maintenance phase. After induction therapy intensity is based on response, which is 
measured by the amount of remaining leukemic cells, also known as minimal residual 
disease (MRD).7 In the Netherlands, currently, the Dutch Childhood Oncology Group 
ALL-11 protocol is used, that stratifi es children with ALL towards standard-, medium- 
and high-risk regimens.
The maintenance phase of the medium-risk regimen plays a central role in this thesis. 
This phase of therapy is meant to eliminate MRD, and to prevent relapses, and consists 
of weekly methotrexate, daily mercaptopurine, vincristine, and dexamethasone therapy. 
Dexamethasone is administered in fi ve-day courses in cycles of three weeks. (Figure 3)
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Figure 2. Increased ALL survival over the last decades (Pieters, NTVG 2010)
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Figure 3. Detail of the maintenance phase of the current Dutch Childhood Oncology Group ALL-11 proto-
col, after discontinuation of asparaginase and anthracyclines.
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Glucocorticoids
Prednisolone and dexamethasone are important components of ALL treatment. Togeth-
er, they are referred to as glucocorticoids, because of their role in regulation of glucose 
levels, their synthesis in the adrenal cortex, and their steroidal structure. Apart from 
being one of the most valuable anti-leukemic agents, glucocorticoids also have anti-
inflammatory and immunosuppressive effects.8 In the current Dutch ALL medium risk 
protocol patients receive dexamethasone at least for 1,5 years during the maintenance 
phase. Dexamethasone pulses have been shown to be highly effective and are more 
potent in the treatment of ALL as compared to prednisone, due to its central nervous 
system penetration9 and higher event free survival.10-13 
A drawback of the treatment with glucocorticoids is the occurrence of serious side ef-
fects11, 14 on metabolism (like hyperglycemia, hypertension, hyperlipidemia), body com-
position, bones and the brain. (Figure 4) Cerebral side effects, or neuropsychological side 
effects, include mood disorders, behavioral problems, cognitive effects, obsession with 
food, and sleeping disorders.15, 16 Based on previous studies, these neuropsychological 
side effects occur in 5-75% of pediatric ALL patients treated with glucocorticoids. This in-
Figure 4. Effects of glucocorticoids. Upper half of circle (grey): therapeutic effects. Lower half of circle: side 
effects.
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troduces a considerable impact on the quality of life during the long period of treatment 
in young children.17 Because of the higher anti-leukemic activity and the higher potency 
to cause metabolic side eff ects11, 14, it is conceivable that dexamethasone induces more 
neuropsychological side eff ects than prednisone. 
Pathophysiology of dexamethasone related-neuropsychological side eff ects
Two receptors are important for the binding of glucocorticoids: the glucocorticoid 
receptor (GR) and the mineralocorticoid receptor (MR). Recent data emphasize that MRs 
in the brain play an important role in the regulation of mood, behavior, cognition and 
sleep.18, 19 The GR and MR are expressed in the same order in the human hippocampus, 
and many other limbic brain regions.20 Based on the high 
affi  nity of the MR for cortisol, it may be the predominant 
receptor during the circadian trough of cortisol secretion, 
while at circadian peak levels the MR and GR mediated 
actions are in balance and determine the stress respon-
siveness of an individual. 
Disturbance of this GR:MR balance, for instance during 
dexamethasone treatment, can deregulate the stress 
system and enhance vulnerability to stress-related 
disorders.21 Dexamethasone has a 30-40 fold higher po-
tency to activate the GR than cortisol, and, in contrast to 
prednisolone, dexamethasone does not bind to the MR.22 
Dexamethasone suppresses the endogenous production 
of cortisol in the adrenals by its suppressive eff ect on the 
hypothalamus-pituitary-adrenal axis. (Figure 5) There-
fore, in dexamethasone treated patients, the cerebral 
MRs are not occupied because the production of cortisol, 
which binds the cerebral MRs in healthy subjects, is fully 
suppressed.22 
In contrast, prednisolone binds the GR, but has a low affi  nity for the MR. Prednisolone 
has an eff ect on the GR and the MR with a ratio of 5:1, so there is still some MR activa-
tion during prednisone treatment.22 This characteristic binding affi  nity explains why 
neuropsychological side eff ects may be more severe during dexamethasone treatment 
compared to prednisone treatment. Treatment with dexamethasone pulses suppresses 
the pulsatile secretion of endogenous cortisol. During repeated exposure to exogenous 
glucocorticoids, the MR:GR balance may change, and thereby aff ecting mood, behavior, 
cognition and sleep.23 
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Figure 5. Schematic overview 
of the hypothalamic-pituitary-
adrenal axis.
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Several studies have shown that MR antagonism or cortisol depletion of the MR can 
cause serious neuropsychological side effects. (Figure 6a) MR knock-out mice showed 
increased anxiety behavior.19 In addition, in rodent studies, MR antagonists have potent 
effects on behavioral responsiveness and coping styles.18 In humans, treatment with 
MR antagonists has been associated with impaired selective attention, impaired recall 
of visual-spatial memory and diminished slow wave sleep.19 Conversely, MR agonism 
had beneficial effects as add-on to anti-depressive treatment24, and a gain of function 
haplotype of the human MR gene is associated with resilience against depression.25 
The differential effects of natural and synthetic glucocorticoids on the brain caused 
by different binding properties to the GR and MR are also illustrated by examples from 
patients. Addison patients, who lack endogenous cortisol, have been found to experi-
ence mood disorders and impairment of cognitive function. They were found to have 
a better performance on cognitive function tests when treated with dexamethasone 
combined with cortisol, compared to dexamethasone only.26 
Side effect directed interventions
Efficacy studies on interventions for dexamethasone-induced neuropsychological 
side effects are mainly limited to case reports. Only Pelletier et al, reported that both 
chlorpromazine and lorazepam were effective at minimizing glucocorticoid-related 
symptoms in a series of ten pediatric ALL patients.27
The various case reports about therapeutic options10, 15, 17, 28-32 are limited to symp-
tomatic treatment of mood and behavioral side effects. For example mood stabilizers, 
antidepressants, electroconvulsive therapy31 and reduction or switch of steroids17, 
have been suggested to be effective in the acute treatment of corticosteroid induced 
psychiatric symptoms.15 Risperidone has been suggested to be effective for treatment 
of agitation, but the onset of mood-stabilizing and antipsychotic effects may take up 
to two weeks.28, 32 In individual cases citalopram30, antipsychotic promethazine29 and 
potassium chloride supplements10 were reported to be effective in case of behavioral 
side effects. Since therapeutic options for dexamethasone-induced neuropsychological 
side effects are scarce, the aim of this thesis was to explore a new therapeutic option, 
with a low patient burden, to diminish these side effects.
Hypothesis
The previous studies in mice and human led to our hypothesis that in children with 
ALL who receive dexamethasone treatment, cortisol depletion of the MR in the brain 
occurs, stronger than in prednisolone-treated patients, thereby causing exacerbation 
of serious neuropsychological side effects.18, 19 (Figure 6b) Hence, we hypothesized that 
these side effects could be ameliorated by adding a physiological dose of the natural 
occurring hormone cortisol (hydrocortisone) that stimulates the MR in the brain in a 
Chapter 1
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Figure 6a. Dexamethasone-treated children with leukemia. GR: glucocorticoid receptor. MR: mineralocor-
ticoid receptor.
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Figure 6b. New hypothesis. GR: glucocorticoid receptor. MR: mineralocorticoid receptor.
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physiological way. An absolute prerequisite is that MR activation by this intervention 
does not interfere with efficacy of the pure glucocorticoids in treating ALL. It is conceiv-
able that reduction of neuropsychological side effects of dexamethasone would lead to 
a major improvement in quality of life in children with ALL, which may also be true for 
patients with Addison’s disease and rheumatologic diseases.
Study design
We tested our hypothesis with a double blind placebo-controlled randomized study 
with a crossover design. The multicenter study was performed in five pediatric oncology 
centers in the Netherlands, that all used one and the same protocol.
Scope of thesis
The aim of this study was threefold:
· The primary aim was to reduce dexamethasone-induced cerebral side effects on 
mood, behavior, sleep, and cognition by an intervention with physiological doses of 
cortisol.
· The secondary aim was to study whether dexamethasone-induced metabolic toxic-
ity (i.e. hyperglycemia, insulin resistance, visceral fat gain, hypertension and hyper-
cholesterolemia) occurred less frequently during intervention treatment compared 
to placebo.
· The third aim was to study the positive predictive value of a novel in vivo diagnostic 
test (salivary very low dose dexamethasone suppression test) on dexamethasone 
side effects.
Outline of this thesis
The first part of the thesis, chapter 2, reviews the difference between the neuropsycho-
logical side effects of dexamethasone and prednisone in pediatric ALL patients. We hy-
pothesized that neuropsychological side effects of dexamethasone could be decreased 
by addition of physiological doses of hydrocortisone during dexamethasone courses. 
Before we could pursue such a trial, we had to ensure safety in a preclinical study, which 
we describe in chapter 3. This provided a safe background for our randomized con-
trolled trial, the “Dexadagen study”. The results of this trial are presented in chapter 4. 
The results of the study on the acute effects of dexamethasone on components of the 
metabolic syndrome are presented in chapter 5. To predict which patients may experi-
ence neuropsychological side effects of dexamethasone we studied the positive predic-
tive value of the salivary very low dose dexamethasone suppression test, as described in 
chapter 6. In chapter 7 we describe the typical exceptional dexamethasone-induced 
changes in eating behavior in a quantitative manner. Finally, we discuss the results of 
this thesis in chapter 8, and an overall summary is provided in chapter 9.
Chapter 1
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neuropsychological side effects than 
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leukemia? A systematic review
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ABSTRAcT
Steroid-induced neuropsychological side effects impact quality of life in children with 
acute lymphoblastic leukemia. Dexamethasone induces more metabolic side effects 
than prednisone. To evaluate whether dexamethasone also leads to more neuropsy-
chological side effects, we reviewed all available literature. Randomized controlled trials 
with neuropsychological function as the primary or secondary outcome did not show 
clinically meaningful differences between dexamethasone and prednisone on cogni-
tion, mood or behavior. 
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inTRoducTion
Corticosteroids, like prednisone and dexamethasone, are important in the treatment of 
acute lymphoblastic leukemia (ALL).1 Dexamethasone is the preferred corticosteroid, 
because of the higher anti-leukemic activity and better central nervous system pen-
etration than prednisone.2-5 Beside the anti-leukemic effect, corticosteroids are known 
for their wide range of side effects. These include hyperlipidemia, hypertension and 
hyperglycemia, but also effects on body composition and bones.4, 6 Early metabolic side 
effects are more apparent in dexamethasone-based than in prednisone-based sched-
ules. Systemically, dexamethasone is about 18 times more potent than prednisone at 
suppressing short-term linear growth and stimulating weight gain, and about nine 
times more potent at suppressing bone turnover.6 In addition, symptomatic osteone-
crosis is an adverse event of dexamethasone in ALL treatment and has become a major 
cause of acute and long-term morbidity, particularly in adolescents.7, 8 Dexamethasone 
also seems to be significantly more potent than prednisone in altering body mass index 
(BMI), insulin resistance9 and causing hyperglycemia and myopathy.2 
According to patients and their parents, the steroid-induced neuropsychological side 
effects are important negative determinants of the quality of life of children during 
cancer treatment.10, 11 The risk of corticosteroid-related neuropsychological side effects 
is dependent on steroid dose and scheduling.12 In view of the fact that pediatric ALL pa-
tients receive steroid pulses for a duration of approximately two years in most protocols, 
the steroid-related side effects on behavior, mood and cognition may potentially have a 
major impact on the child’s daily life and development. 
Because of the higher anti-leukemic activity and the higher potency to cause meta-
bolic side effects, it is conceivable that more neuropsychological side effects, affecting 
behavior, mood and/or cognition, may occur with dexamethasone than with predni-
sone. However, previous reports seem to indicate conflicting outcomes on this point. 
Therefore we investigated the evidence by reviewing all published studies comparing 
neuropsychological side effects between dexamethasone and prednisone in children 
treated for ALL. 
meThodS
The review included English-language studies of children, determined through a sys-
tematic search in the database of MEDLINE (1960 till December 2013), EMBASE (1960 till 
December 2013) and The Cochrane Library (till December 2013). 
Search terms we used are (child*[tw] OR toddler*[tw] OR boy*[tw] OR girl*[tw] 
OR pediatr*[tw] OR paediatr*[tw] OR (adolescen*[tw] NOT adults[mesh])) AND 
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(Corticosteroid*[tw] OR Corticoid*[tw] OR dexamethason*[tw] OR prednisone*[tw] 
OR prednisolon*[tw]) AND (Mood Disorders[mesh] OR cognition[mesh] OR Cogni-
tion Disorders[mesh] OR behavior[mesh] OR Neuropsycholog*[tw] OR depress*[tw] 
OR aff ect*[tw] OR mood*[tw] OR cognit*[tw] OR behavio*[tw] OR fatigue*[tw] OR 
sleep*[tw] OR mania*[tw] OR panic*[tw] OR mental*[tw] OR eating behavior*[tw] OR 
eating disorder*[tw] OR food obsession* [tw] OR craving*[tw] OR hyperphagia*[tw] OR 
anxiety*[tw] OR attention*[tw] OR memory*[tw] OR executive function*[tw] OR process-
ing speed*[tw]) AND (leukaemia*[tw] OR leukemi*[tw] OR ALL[tw]). 
Articles were selected on the basis of title and abstract by two independent review-
ers (LTW and MAHH) using the following inclusion criteria: (1) children with leukemia 
/ ALL were receiving dexamethasone and/or prednisone; (2) neuropsychological side 
eff ects (mood, cognition, behavior, sleep) were compared between dexamethasone and 
prednisone; (3) original research; (4) written in English. We excluded case series (<10 
subjects). All selected articles were 
assessed in full text by two review-
ers to ensure eligibility. Discrepan-
cies between reviewers during 
the review process were solved by 
discussion with the co-authors. In 
total 13 studies met the inclusion 
criteria (Figure 1). We evaluated 
eligible studies on study design, 
quality of the study, consistency 
and directness of the study by 
the Grading of Recommendations 
Assessment Development and 
Evaluation (GRADE) criteria of the 
GRADE working group.13, 14
ReSuLTS
RcTs with neuropsychological side eff ects as primary endpoint
Five randomized controlled trials (RCTs) have compared neuropsychological side eff ects 
of dexamethasone and prednisone by a validated neuropsychological assessment in 
children with ALL as primary endpoint.15-19 These trials have a high level of evidence, 
because of their study design without important limitations or inconsistencies. Three of 
the RCTs focused on the acute steroid-induced mood and behavioral changes15, 16, 18, and 
two RCTs focus on long term neurocognitive17, 19 as well as behavioral eff ects17, 19. All fi ve 
Potentially 
relevant articles 
(n=234) 
Retrieved in full 
text (n=48) 
Included articles 
(n=13) 
Excluded on basis of 
title and abstract 
(n=186) 
Articles added after 
handsearching (n=3) 
Articles excluded 
(n=38) 
Figure 1. Selection of articles.
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trials included steroid randomization, and used validated questionnaires or neurocogni-
tive tests. 
Behavior and mood. The three trials investigating acute steroid-related effects on 
mood and behavior had a different period of assessment with a range from induction 
therapy to one year from diagnosis. Despite these differences in period of assessment, 
the investigators showed consistent results and reported no significant difference in 
side effects on mood and behavior between patients treated with dexamethasone or 
prednisone (dexamethasone: prednisone dose ratio was considered 1:6-7). Mood and 
behavior was assessed during steroids by the parent-reported questionnaires; the 
Pediatric Quality of Life Inventory (PedsQL), the Child Behavior Checklist (CBCL) or the 
Behavior Rating Inventory of Executive Function (BRIEF).15, 16, 18 The MRC UK ALL-99 study 
used the PedsQL that rates the child’s physical, social and emotional function, at 3-6 
months (T1) after diagnosis and one year (T2) after diagnosis in 45 mothers of a child 
with ALL.15 The mean age of the children at T1 was 7.3 years. An increase in physical, 
social and emotional problems over the first year of therapy was shown with use of 
the PedsQL for both steroids, without significant differences between dexamethasone 
and prednisone.15 The CBCL was used in the AIEOP-BFM study and the DFCI CP00-01 
study to assess the child’s behavior via parent-report.16, 18 In the AIEOP-BFM study 12 
of 37 ALL patients received dexamethasone during the first 28 days of treatment. 67% 
of children in the dexamethasone group showed more adverse psychological reac-
tions after 4 weeks of continuous steroids, compared to 48% in the prednisone group, 
but this difference was not significant (OR=2.2, 95% CI: 0.5-9.1).16 Side effects during 
continuation phase were measured in the DFCI CP00-01 study18, where parents of 62 
ALL patients reported behavior at baseline, after five days of steroids, and after one and 
two weeks off-steroids. They did not show a significant difference in behavioral side ef-
fects between the dexamethasone and prednisone treated group.18 Interestingly, older 
children (≥6 years) treated with a standard risk protocol showed more problem behavior 
than those treated with the high-risk protocol, despite a threefold higher steroid dose 
for high-risk patients. The investigators hypothesized that more frequent delivery of 
intrathecal chemotherapy to standard risk patients (every 9 weeks vs. every 18 weeks) 
during the first six months of continuation therapy could potentially be contributory.18
Waber et al.19 assessed long-term side effects on behavior and mood in the DFCI CP 
00-01 protocol at a median time of 5.8 years post diagnosis, using parent-reported 
questionnaires; the BRIEF and the Behavioral Assessment System for Children-2 (BASC-
2). They could not show a difference in behavioral and mood effects on the long term 
between patients treated with the two drugs.19
cognition. Beside the trials on mood and behavior, two RCTs investigated the steroid-
induced long-term neurocognitive side effects.17, 19 Both trials had randomized steroid 
arms and used validated tests to assess neurocognitive function at a mean time of 9.8 
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years (CCG trial)17 and a median time of 5.8 years (DFCI trial)19 since diagnosis. The CCG 
trial investigated the long-term effect on intelligence, academic achievement, process-
ing speed, concentration, memory and visual-motor integration in 92 childhood ALL 
survivors (mean: 3.3 years, range: 6-16 years).17 They only found a minor negative effect 
of dexamethasone compared to prednisone on word reading (P=0.02), which was not 
clinically significant. The groups performed similarly on attention-concentration, visual-
motor integration, numeric operations, spelling and memory. Also, there was no signifi-
cant difference in the parents’ report of neurological complications, psychotropic drug 
use, and need of special education services between dexamethasone and prednisone.17 
The DFCI trial prospectively compared the difference in neurocognitive outcome 
between dexamethasone and prednisone in 170 survivors of ALL at a median time of 
5.8 years post diagnosis by Wechsler tests.19 The assessing psychologists were blinded 
for the steroid that was administered. Steroid type did not influence most of the out-
comes. Only patients on the dexamethasone arm performed poorer on a measure of 
fluid reasoning (P=0.02). It is however important to stress that mean scores on nearly all 
outcomes in this study approximated the mean for the general population. A limitation 
of the DFCI trial is the inclusion of patients with cranial radiation in their treatment, so 
any differences attributed to corticosteroid exposure could in fact be confounded by 
radiation. They did not adjust for radiation dose and interaction between corticosteroids 
and radiation dose was not checked. The results of this trial generally confirmed the 
results of the CCG trial. In both studies the dexamethasone group used more special 
education, but differences were not significant (DFCI trial: dexamethasone 33% vs. 
prednisone 20%, P=0.09).17, 19 
RcTs with neuropsychological side effects as secondary endpoint
Behavior and mood. Beside the RCTs using neuropsychological side effects as primary 
endpoint, three large non-blinded trials randomizing prednisone versus dexametha-
sone studied acute neuropsychological side effects as secondary endpoint.2, 4, 20 Unfor-
tunately, no validated questionnaires were used to measure the effects on mood and 
behavior, because the primary outcome was event free survival2, 4, 20 and central nervous 
system relapse2. This lack of standard validated tests degrades the level of evidence, de-
spite the high quality study design. Fortunately, all studies measured side effects during 
similar phases of treatment, but they all lack a report on cognitive effects. The three RCTs 
consistently reported more acute side effects on mood and behavior in patients treated 
with dexamethasone compared to the prednisone group, although the difference was 
small and only significant in the MRC study4, which was the only one that included 
patients > 9 years. Igarashi et al.20 included ALL patients (n=359) under the age of 10 and 
found neuropsychiatric effects, such as severe agitation, in 1.7% of the children treated 
with dexamethasone during induction and intensification. No psychiatric side effects 
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were found in the prednisone arm of this study.20 The CCG-1922 trial (n=1060) limited 
their steroid randomization and analysis to the induction phase, and no significant dif-
ferences were found in neuropsychological side effects between both steroids.2 The UK 
MRC ALL-97/99 trial (n=1603, 1-18 years) reported behavioral problems in 5.9% of the 
dexamethasone group during induction compared to 1.4% in the prednisone group 
(P=0.02).4 The reported side effects varied widely, ranging from mood swings to severe 
depression and violence towards themselves or others. Three patients (0.4%) had a 
dexamethasone induced delusional psychosis.4 Cessation of dexamethasone treatment 
led to rapid disappearance of symptoms. After cessation of steroids these patients were 
switched to prednisone with no reported significant recurrence of behavioral problems. 
No patients treated with prednisone developed severe mood changes that led to reduc-
tion of or discontinuation of steroids.4
Prospective observational studies
Behavior and mood. Two studies investigated side effects on mood and behavior of 
prednisone versus dexamethasone prospectively, but not in a randomized setting.21, 22 
These studies used validated questionnaires and psychological function was their pri-
mary outcome. Parent-reported CBCL and PedsQL questionnaires were used to assess 
behavioral and mood changes during treatment and two years post-therapy.21, 22 Both 
studies found relatively more behavioral problems during dexamethasone compared 
to the prednisone group.21, 22 According to Pound et al.22 this difference was limited to 
older children (≥6 years). They investigated acute steroid-induced behavioral toxicity 
by parent report of 43 ALL patients with a mean age of 7 years. CBCL questionnaires 
were filled out after a 5-day steroid course and again after 2 or 3 weeks (off-steroids). 
They found significantly more total behavioral problems, affective problems and anxiety 
during dexamethasone compared to prednisone in the children above the age of five. 
Unfortunately, the number of patients treated with prednisone in this study was small 
(10 of 43), potentially influencing the findings.22 
Marcoux et al.21 used the CBCL at six time points during 4 years from diagnosis. The 
ALL patients had a mean age of 6 years at diagnosis. A trend for more externalized 
behavioral problems (disruptive, hyperactive, and aggressive behaviors) was observed 
during therapy in the dexamethasone group (P=0.057). However, the rate of external-
ized behavioral problems (20%) in the study population was relatively low.21 
cognition. Beside the two observational reports on mood and behavior, steroid-
induced long-term effects on cognition were analyzed by three prospective non-
randomized studies.23-25 All studies used validated cognitive tests. The three studies 
differ in type of cognitive tests, steroid dose, and time of assessment. The observational 
study of Buizer et al.25 assessed attentional function by the Amsterdam Neuropsycho-
logical Tasks (ANT) program in ALL patients at a mean time of 5.7 years after diagnosis. 
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Children treated with dexamethasone-based protocols (DCLSG ALL-6 and -9) did not 
differ in attentional function compared to children treated with prednisone-based 
protocols (DCLSG ALL-7 and -8). Interestingly, more subtle post-treatment attentional 
deficits were found in children that received intensified treatment. In view of the fact 
that the cumulative dose of intravenous methotrexate was the only treatment factor 
that was significantly higher in the ALL-intensified treatment group compared to the 
ALL-standard treatment group, these results suggest that the dosage of methotrexate is 
a factor in subtle post-treatment attentional deficits.25 On the contrary, Waber et al.24 and 
Edelmann et al.23 showed a negative long-term effect of dexamethasone on cognition. 
The prospective DFCI study of Waber et al.24 assessed cognitive function in ALL patients 
at a mean time of 4 years post diagnosis. The mean age of the patients at diagnosis 
was 3.7 years (DFCI 91-01: dexamethasone) and 5.3 years (DFCI 95-01: prednisone). They 
found significantly more neurocognitive impairment regarding measures of academic 
achievement (reading comprehension and arithmetic calculation), working memory, 
and learning disabilities in the dexamethasone group.24 However, limitations of the 
study were the use of historic controls, the younger mean age of the dexamethasone 
group, which could possibly affect the outcome17, and relatively higher rates of cranial 
radiation in the dexamethasone group (70% vs. 50% in the prednisone group, although 
not significant), which has a known effect on cognition. Very recently, Edelmann et al.23 
studied neurocognitive function in 38 adult survivors of childhood ALL of the TOTXIIIA 
(prednisone based) and TOTXIIIB (dexamethasone based) protocol with a median follow 
up time of 13 years (dexamethasone) and 16 years (prednisone) post diagnosis. They 
found lower performance in measures of short-term and long-term memory (P<0.04), 
intelligence (P=0.03), and academic tasks (P<0.009) in adult ALL survivors (range: 19-32 
years) treated with dexamethasone.23 The effect sizes were in the range of 3/4 to 1 stan-
dard deviation between groups.23 They did not correct for follow-up time in the analyses. 
The results could be influenced by the variation in cumulative steroid dose between 
the subgroups of the St Jude trial. The patients in the TOTXIIIA protocol received 14% 
less steroids than the dexamethasone group.23 Survivors in CCG study17 were treated 
with less dexamethasone, compared to patients enrolled in the St Jude trial23 and the 
prospective DFCI trial24. The subgroups in the TOTAL XIII study also differed significantly 
in the educational attainment, which may have been induced by the cognitive impair-
ment of dexamethasone. However, no information on SES background was provided in 
this study. In the DFCI CP00-01 study19 and the CCG study17 patients treated with dexa-
methasone also needed more special education such as remedial teaching, compared to 
the prednisone group, but the difference between the dexamethasone and prednisone 
groups was not significant (Table I).
27
Review
Ta
bl
e 
i. 
In
cl
ud
ed
 s
tu
di
es
Tr
ia
l
Ag
e 
at
 D
x,
 a
ut
ho
r
n
 =
St
ud
y
de
si
gn
A
ss
es
sm
en
t
St
er
oi
d 
do
se
Tr
ea
tm
en
t 
ph
as
e
Be
ha
vi
or
 a
nd
 
m
oo
d
co
gn
it
io
n
St
ud
y 
lim
it
at
io
n
m
Rc
 u
K 
A
LL
-9
9
3-
18
 y
rs
(E
is
er
, 2
00
6)
45
RC
T
Pe
ds
Q
L
D
EX
: 6
.5
 m
g/
m
²/
d
PR
ED
: 4
0 
m
g/
m
²/
d
3 
m
nt
hs
 –
 1
 y
r 
po
st
 D
x
ns
no
t t
es
te
d
-
A
ie
o
P-
BF
m
 A
LL
 2
00
0
4-
18
 y
rs
(F
el
de
r-
Pu
ig
, 2
00
7)
37
RC
T
CB
CL
D
EX
: 1
0 
m
g/
m
²/
d
PR
ED
: 6
0 
m
g/
m
²/
d
W
k 
1 
– 
19
ns
no
t t
es
te
d
R 
on
ly
 <
 1
0 
yr
s
d
Fc
i c
P 
00
-0
1
1-
 1
6 
yr
s
(M
ra
ko
ts
ky
, 2
01
1)
62
RC
T
CB
CL
, B
RI
EF
D
EX
: 6
 m
g/
m
²/
d
PR
ED
: 4
0 
m
g/
m
²/
d
Co
nt
in
ua
tio
n
ns
no
t t
es
te
d
-
cc
G
-1
92
2
SR
 A
LL
, 6
-1
6 
yr
s
(K
ad
an
, 2
00
9)
92
RC
T
W
IS
C-
IV
, W
IA
T-
II-
A
, 
CM
S,
 C
PT
, B
ee
ry
R 
in
 In
du
ct
io
n:
D
EX
: 6
 m
g/
m
²/
d
PR
ED
: 4
0 
m
g/
m
²/
d
M
ea
n 
9.
8 
yr
s 
po
st
 D
x 
(S
D
 0
.5
)
no
t t
es
te
d
D
EX
: 1
/3
 S
D
 lo
w
er
 
on
 w
or
d 
re
ad
in
g 
(P
=0
.0
2)
-
d
Fc
i c
P 
00
-0
1
1-
18
 y
rs
(W
ab
er
, 2
01
3)
17
0
RC
T
W
A
SI
, W
IS
C-
IV
, 
W
A
IS
-II
I, 
RO
CF
, 
BA
SC
-2
, B
RI
EF
,
W
J-
III
, T
M
L
D
EX
: 6
 (S
R 
+ 
H
R)
 /
18
 (H
R 
in
t)
 m
g/
m
²/
d 
PR
ED
: 4
0 
(S
R 
+ 
H
R)
/
12
0 
(H
R 
in
t)
 m
g/
m
²/
d
4–
9 
yr
s 
po
st
 D
x
(m
ed
ia
n 
5.
8 
yr
s)
ns
D
EX
: l
ow
er
 
sc
or
e 
on
 fl
ui
d 
re
as
on
in
g 
(P
=0
.0
2)
 X
RT
 s
ub
gr
ou
p
cc
G
-1
92
2
SR
 A
LL
, 1
-9
 y
rs
(B
os
tr
om
, 2
00
3)
10
60
RC
T
-
R 
in
 In
du
ct
io
n:
D
EX
: 6
 m
g/
m
²/
d
PR
ED
: 4
0 
m
g/
m
²/
d
In
du
ct
io
n
Co
nt
in
ua
tio
n
M
ai
nt
en
an
ce
D
EX
: 1
.1
 %
PR
ED
: 0
 %
no
t t
es
te
d
N
o 
as
se
ss
m
en
t
m
Rc
 A
LL
-9
7/
99
SR
/H
R 
A
LL
, 1
-1
8 
yr
s
(M
itc
he
ll,
 2
00
5)
16
03
RC
T
-
D
EX
: 6
.5
 m
g/
m
²/
d
PR
ED
: 4
0 
m
g/
m
²/
d
In
du
ct
io
n
M
ai
nt
en
an
ce
D
EX
: 5
.9
 %
PR
ED
: 1
.4
%
 
(P
=0
.0
2)
no
t t
es
te
d
 N
o 
as
se
ss
m
en
t
To
ky
o 
L9
5-
14
SR
/IR
 A
LL
, <
10
 y
rs
(Ig
ar
as
hi
, 2
00
5)
35
9
RC
T
-
D
EX
: 8
 (i
nd
) /
 6
 (i
nt
)
m
g/
m
²/
d
PR
ED
: 6
0 
(in
d)
 / 
40
(in
t)
 m
g/
m
²/
d
In
du
ct
io
n
In
te
ns
ifi
ca
tio
n
D
EX
: 1
.7
%
PR
ED
: 0
%
no
t t
es
te
d
 N
o 
as
se
ss
m
en
t
Chapter 2
28
Ta
bl
e 
i. 
In
cl
ud
ed
 s
tu
di
es
 (c
on
tin
ue
d)
Tr
ia
l
Ag
e 
at
 D
x,
 a
ut
ho
r
n
 =
St
ud
y
de
si
gn
A
ss
es
sm
en
t
St
er
oi
d 
do
se
Tr
ea
tm
en
t 
ph
as
e
Be
ha
vi
or
 a
nd
 
m
oo
d
co
gn
it
io
n
St
ud
y 
lim
it
at
io
n
d
Fc
i 2
00
5-
01
, c
o
G
-
03
31
, 0
23
2 
an
d 
04
34
SR
/H
R,
 3
-1
8 
yr
s
(P
ou
nd
, 2
01
2)
43
O
bs
er
va
-
tio
na
l
CB
CL
, P
ed
sQ
L
un
kn
ow
n
M
ai
nt
en
an
ce
6-
18
 y
rs
:
D
EX
 >
PR
ED
: 
to
ta
l
+ 
aff
ec
tiv
e 
pr
ob
le
m
s 
an
d 
an
xi
et
y
3-
5 
yr
s:
 n
s
no
t t
es
te
d
Sm
al
l s
ub
gr
ou
ps
:
76
.7
%
 d
ex
23
.2
%
 p
re
d.
d
Fc
i 9
1-
01
 o
r
d
Fc
i 9
5-
01
SR
/H
R,
 0
-1
7 
yr
s
(M
ar
co
ux
, 2
01
2)
13
8
O
bs
er
va
-
tio
na
l
CB
CL
D
EX
: 6
 (S
R)
 / 
18
 (H
R)
 m
g/
m
²/
d 
PR
ED
: 4
0 
(S
R)
 / 
12
0 
(H
R)
 
m
g/
m
²/
d
Fr
om
 D
x 
w
ith
 
4y
rs
 fo
llo
w
-u
p
D
EX
: t
re
nd
 fo
r 
m
or
e
ex
te
rn
al
iz
ed
 
be
ha
vi
or
al
 
pr
ob
le
m
s 
(P
=0
.0
57
)
no
t t
es
te
d
-
d
Fc
i 9
1-
01
 (d
ex
)
d
Fc
i 8
7-
01
 (p
re
d)
SR
/H
R 
, 6
-1
2 
yr
s
(W
ab
er
, 2
00
0)
67
O
bs
er
va
-
tio
na
l
W
IS
C-
R,
 W
IS
C-
III
, 
RO
CF
D
EX
: 6
 (S
R)
 / 
18
 (H
R)
 m
g/
m
²/
d 
PR
ED
: 4
0 
(S
R)
 / 
12
0 
(H
R)
 
m
g/
m
²/
d
M
ea
n 
4 
yr
s 
po
st
 
D
x 
(S
D
 0
.6
)
no
t t
es
te
d
D
EX
: w
or
se
 
on
 m
ea
su
re
s 
of
 a
ca
de
m
ic
 
ac
hi
ev
em
en
t 
(P
<0
.0
2)
, w
or
ki
ng
 
m
em
or
y 
(P
<0
.0
3)
, 
an
d 
le
ar
ni
ng
 
(P
<0
.0
2)
XR
T 
su
bg
ro
up
d
cL
SG
 A
LL
-6
, A
LL
-7
,
A
LL
-8
, A
LL
-9
SR
/IR
/H
R,
 4
.9
 y
rs
(B
ui
ze
r, 
20
05
)
36
O
bs
er
va
-
tio
na
l
A
N
T
D
EX
: 6
 m
g/
m
²/
d
(A
LL
-6
 a
nd
 -9
)
PR
ED
: 6
0 
/ 1
00
 m
g/
m
²/
d 
(A
LL
-7
 a
nd
 -8
)
M
ea
n 
5.
7 
yr
s 
po
st
 D
x 
(S
D
 3
.4
)
no
t t
es
te
d
ns
 (0
.2
5 
< 
P<
 
0.
99
)
Sm
al
l s
ub
gr
ou
ps
29
Review
Ta
bl
e 
i. 
In
cl
ud
ed
 s
tu
di
es
 (c
on
tin
ue
d)
Tr
ia
l
Ag
e 
at
 D
x,
 a
ut
ho
r
n
 =
St
ud
y
de
si
gn
A
ss
es
sm
en
t
St
er
oi
d 
do
se
Tr
ea
tm
en
t 
ph
as
e
Be
ha
vi
or
 a
nd
 
m
oo
d
co
gn
it
io
n
St
ud
y 
lim
it
at
io
n
To
TX
iii
A
, T
o
TX
iii
B
3-
18
 y
rs
(E
de
lm
an
n,
 2
01
3)
38
O
bs
er
va
-
tio
na
l
W
A
SI
, W
J-
III
 te
st
 o
f 
ac
hi
ev
em
en
t, 
TM
L
M
ai
nt
en
an
ce
:
D
EX
: 8
 m
g/
m
²/
d
PR
ED
: 4
0 
m
g/
m
²/
d
12
-1
7 
yr
s 
po
st
- 
D
x
(m
ed
ia
n:
 1
5.
9 
(p
re
d)
13
.3
 (d
ex
))
no
t t
es
te
d
D
EX
: w
or
se
 
on
 m
ea
su
re
s 
of
 s
ho
rt
-t
er
m
 
an
d 
lo
ng
-t
er
m
 
m
em
or
y 
(P
<0
.0
4)
, 
in
te
lli
ge
nc
e 
(P
=0
.0
3)
, a
nd
 
ac
ad
em
ic
 ta
sk
s 
(P
<0
.0
09
)
Sm
al
l s
am
pl
e 
si
ze
St
ud
ie
s o
n 
de
xa
m
et
ha
so
ne
 (D
EX
) a
nd
 p
re
dn
is
on
e 
(P
RE
D
) w
er
e 
gr
ad
ed
 (G
RA
D
E 
sy
st
em
) a
s h
ig
h 
(li
gh
t g
re
y)
 o
r l
ow
 (d
ar
k 
gr
ey
) l
ev
el
 o
f e
vi
de
nc
e.
 Tr
ia
ls
 o
n 
lo
ng
-t
er
m
 e
ffe
ct
s 
ar
e 
gr
ey
. V
ar
io
us
 a
ss
es
sm
en
ts
 w
er
e 
us
ed
: C
hi
ld
’s 
Be
ha
vi
ou
r C
he
ck
lis
t (
CB
CL
), 
Be
ha
vi
ou
ra
l R
at
in
g 
In
ve
nt
or
y 
of
 E
xe
cu
tiv
e 
Fu
nc
tio
n 
(B
RI
EF
), 
Be
ha
vi
ou
ra
l A
ss
es
sm
en
t S
ys
te
m
 
fo
r 
Ch
ild
re
n 
(B
A
SC
), 
Pe
di
at
ric
 Q
ua
lit
y 
of
 L
ife
 In
ve
nt
or
y 
(P
ed
sQ
L)
, W
ec
hs
le
r 
In
te
lli
ge
nc
e 
Sc
al
e 
fo
r 
Ch
ild
re
n-
 F
ou
rt
h 
Ed
iti
on
 (
W
IS
C-
IV
), 
W
ec
hs
le
r 
In
di
vi
du
al
 A
ch
ie
ve
m
en
t 
Te
st
–S
ec
on
d 
Ed
iti
on
–A
bb
re
vi
at
ed
 (W
IA
T-
II-
A
), 
Be
er
y 
D
ev
el
op
m
en
ta
l T
es
t o
f V
is
ua
l M
ot
or
 In
te
gr
at
io
n 
(B
ee
ry
), 
Co
nn
er
s’ 
Co
nt
in
uo
us
 P
er
fo
rm
an
ce
 T
es
t I
I (
CP
T)
, C
hi
ld
re
n’
s 
M
em
or
y 
Sc
al
e 
(C
M
S)
, R
ey
-O
st
er
rie
th
 C
om
pl
ex
 F
ig
ur
e 
Te
st
 (R
O
CF
), 
W
ec
hs
le
r A
bb
re
vi
at
ed
 S
ca
le
 o
f I
nt
el
lig
en
ce
 (W
A
SI
), 
W
oo
ds
to
ck
-J
oh
ns
on
-II
I T
es
t o
f A
ch
ie
ve
m
en
t (
W
J-
III
 
te
st
 o
f a
ch
ie
ve
m
en
t)
 , 
Te
st
 o
f M
em
or
y 
an
d 
Le
ar
ni
ng
 (
TM
L)
, A
m
st
er
da
m
 N
eu
ro
ps
yc
ho
lo
gi
ca
l T
as
ks
 c
om
pu
te
r-
ai
de
d 
as
se
ss
m
en
t 
pr
og
ra
m
 (A
N
T)
. D
x 
= 
di
ag
no
si
s. 
XR
T 
= 
cr
an
ia
l r
ad
io
th
er
ap
y.
 R
 =
 ra
nd
om
iz
at
io
n.
 n
s 
= 
no
t s
ig
ni
fic
an
t.
Chapter 2
30
diScuSSion
Taking all trials into consideration, we found that half of the studies report more 
neuropsychological side effects with dexamethasone compared to prednisone, both 
on short-term as well as on long-term in children with ALL.4, 21-24 However, if we focus 
on RCTs with neuropsychological outcome as primary endpoint, there is no significant 
difference in short-term and long-term effects on mood and behavior between both 
steroids15, 16, 18, 19 and there is only little indication of a negative long-term effect on 
cognition of dexamethasone compared to prednisone in the absence of a clinically 
significant difference17, 19. In regard to the effectiveness and the ultimate aim of the treat-
ment of childhood cancer, that is to say, with a view to the cure, this fact is reassuring, 
for dexamethasone clearly carries an advantage over prednisone by virtue of its greater 
beneficial potential.2-5 
In order to accurately evaluate the acute steroid-related effects on mood and behavior 
based on the literature it is important to take a few problems into account. First, the 
discrepancy in acute effects on behavior and mood between the MRC trial4 and some 
observational studies21, 22, 24 on one hand and the three direct RCTs15, 16, 18 on the other 
hand, which is primarily due to study design but could also be influenced by the lack 
of a subdivision in age groups in the RCTs.15, 16, 18 It is conceivable that especially older 
children, as reported by Pound et al.22, may have more side effects on dexamethasone 
compared to prednisone.
Furthermore, it is remarkable that clinicians report less4 mood and behavioral side 
effects than parents16 by validated tests. An underestimation of the frequency of side ef-
fects is possible in the RCT’s with psychological side effects as secondary endpoint.2, 4, 20 
Another difficulty with assessment of steroid related mood and behavioral changes is 
the use of parent-reported questionnaires in all trials, which could deviate from the 
child’s opinion. Unfortunately, assessment of behavior and mood with self-reported 
questionnaires was not performed, although all studies included older patients, so they 
could have used self-reported questionnaires. 
To accurately assess the acute side effects on mood and behavior and compare the 
side effects between steroids, a double blind RCT would be required. Such a RCT may 
currently be difficult to pursue, because of the proven higher anti-leukemic activity of 
dexamethasone.2 The results of the prospective studies and RCTs on mood and behavior 
show contradictory results. However, it is important to note that the prospective studies 
apart from their inferior study design, have either a small sample size or report relatively 
low behavioral problems. The unexpected finding of the DFCI study18 about the influ-
ence of intrathecal chemotherapy frequency on behavioral problems will need further 
investigation.
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In contrast to results of the trials on mood and behavior, the data on cognitive ef-
fects of steroids seem to be more in agreement. No study has compared differences of 
short-term cognitive effects between dexamethasone and prednisone. The prospective 
DFCI trial24 and the recent SJCRH study23 suggest that survivors of childhood ALL treated 
with dexamethasone are at higher risk for long-term memory problems 4 years24 but 
also 16 years23 post diagnosis. In contrast, the DCLSG study25 reported no difference in 
attentional function 4 years post diagnosis comparing both steroids, but suggests that 
the cumulative dose of intravenous methotrexate is a factor in subtle post-treatment at-
tentional deficits. The randomized trials17, 19 on long-term cognitive function only show a 
subtle difference between dexamethasone and prednisone, limited to a minor decrease 
in word reading without clinical significance on dexamethasone in the CCG trial17, and 
a minor decrease on a IQ measure of fluid reasoning on dexamethasone in the blinded 
DFCI RCT19. Mean scores on nearly all outcomes approximated the mean for the general 
population in the RCTs. The discrepancies between results of prospective studies and 
RCTs could be due to differences in time of follow-up, age at diagnosis, cumulative dose 
of glucocorticoid administered, or neurocognitive assessment procedures.23 An exten-
sive St. Jude Lifetime Cohort Study demonstrated that in adult survivors of childhood 
ALL previous use of dexamethasone was associated with significant neurocognitive 
impairment (on attention and executive function) after a median follow-up time of 26 
years since diagnosis, adjusting for methotrexate exposure.26 Buizer et al.25 did not find 
an association between previous dexamethasone exposure and attentional dysfunction 
six years after diagnosis (at a mean age of 11 years). The differences in elapsed time since 
diagnosis and neurocognitive tests could contribute to the different outcomes. However, 
the findings of the St. Jude Lifetime Cohort Study underline the importance of further 
investigation of the effects of both steroids on long-term neurocognitive function.
Based on this review of the literature, we conclude that there is no high-level of evi-
dence confirming a significant difference in short-term effects of dexamethasone and 
prednisone on behavior and mood in children with ALL. Moreover, there is no clinically 
significant difference in long-term cognitive effects between both steroids. 
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Dexamethasone is the preferred glucocorticoid in the treatment of pediatric acute 
lymphoblastic leukemia (ALL), as its anti-leukemic activity in vitro is 7 to 16-fold higher 
than that of prednisolone1 and it is associated with a higher event-free survival than 
prednisone.2 However, serious neuropsychological side-effects have been described in 
5-75% of children with ALL during treatment with dexamethasone, as reflected by ob-
session with food, sleeping disorders, and by mood, cognition and behavioral problems, 
sometimes even resulting in psychosis and depression.3, 4 This may tremendously affect 
patients’ quality of life during the two years of ALL treatment.3
These neuropsychological side effects may be caused by binding of dexamethasone 
to the glucocorticoid receptor (GR) expressed in brain tissues.4 However, recent studies 
imply that the mineralocorticoid receptor (MR) is important in the regulation of mood, 
behavior and sleep.5, 6 Cortisol can bind to both the MR and the GR, although cortisol has 
a 10-fold higher affinity for the MR.5 In contrast, dexamethasone does not bind to the MR 
and its potency to activate the GR is 30- to 40-fold higher than that of cortisol.7 Similarly, 
prednisolone has a higher binding-affinity (~5-fold) for GR compared to MR.7 Recent 
data suggest that the MR in dexamethasone-treated patients is not fully saturated by 
endogenous cortisol.7 This is caused by a reduced production of cortisol due to the fact 
that dexamethasone triggers a negative feedback-loop affecting the hypothalamus-
pituitary-adrenal axis.7 Studies in animals and small case series of patients with a de-
pression suggest that a reduced level of cortisol has serious effects on mood, behavior 
and sleep.5, 6 Based on these findings we hypothesize that dexamethasone-induced 
depletion of cortisol in the brain may cause or exacerbate the neuropsychological 
side-effects in children suffering from ALL. It is therefore feasible that administration of 
hydrocortisone (i.e. the naturally occurring cortisol now used as medicine) may reduce 
the neuropsychological side effects associated with dexamethasone treatment by 
circumventing this negative feedback-loop through direct activation of MR-mediated 
signaling as visualized in Supplemental Figure S1. To enable the clinical application of 
such an intervention strategy, however, an absolute prerequisite is that MR activation 
does not interfere with the anti-leukemic efficacy of glucocorticoids (dexamethasone 
and prednisolone). To this aim, we examined the MR and GR levels and the effect of 
hydrocortisone on the cytotoxicity induced by dexamethasone and prednisolone in 
leukemic cell lines and freshly obtained ALL cells of children with newly diagnosed ALL. 
The mRNA levels of MR and GR expressed in leukemic patients’ cells were estimated by 
probeset 205259_at for MR and 232431_at for GR from a previously published set of gene 
expression data generated using Affymetrix U133 plus 2.0 gene arrays.8, 9 These levels 
were confirmed by RTqPCR (see supplemental methods). The genetic subtype of each 
patient was determined by means of FISH, RT-PCR and by utilizing a 110-probeset gene 
expression signature which enables the classification of ALL in (cytogenetic) subtypes.8 
A methyl-thiazol-tetrazolium salt drug cytotoxicity assay (MTT-assay) was used to select 
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cases being either in vitro highly sensitive, intermediate resistant or highly resistant to 
prednisolone, using exactly the same cut-off levels as previously reported.9 These lethal 
concentrations for 50% of the cells (LC50) have been shown to be predictive for clinical 
outcome of children with newly diagnosed ALL.9-11 
The mRNA levels of MR and GR did not differ between glucocorticoid sensitive, 
intermediate and resistant patients’ ALL cells. Interestingly, the ETV6-RUNX1+ subtype 
expressed higher MR mRNA levels than the other ALL subtypes (p≤0.001), although ex-
pression levels were still relatively low (Figure 1A). RT-qPCR analysis of MR and GR levels 
indicated that the mRNA levels obtained by both methods were strongly correlated for 
MR (R=0.88, p<0.0001 (Supplemental Figure S2A) and moderately for GR (R=0.48, p=0.02 
(Supplemental Figure S2B). RT-qPCR also confirmed that ETV6-RUNX1+ cells have higher 
MR mRNA levels than other subtypes of ALL (p≤0.001) (Supplemental Figure S2A). GR 
mRNA levels were higher compared to MR mRNA levels, in both microarray and RT-qPCR 
analyses (Figure 1C). 
In order to study whether hydrocortisone can be safely combined with dexamethasone 
in the treatment of ALL, we first tested hydrocortisone and corticosteroids in four 
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Figure 1. Leukemic cells express low levels of the MR. 
A. MR expression levels in leukemic cells of different 
cytogenetic ALL subtypes. B. GR expression levels 
in the same leukemic cell samples as is A. c. Relative 
expression levels of MR and GR in leukemic cells of 
ALL patients as determined by RT-qPCR (compared 
to the input-control gene RPS20).  Data were ana-
lyzed by the Mann-Whitney U test (***= p≤0.001).
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Figure 2. Hydrocortisone does not induce resistance to glucocorticoids in leukemic cell lines. 
A. Cytotoxicity of hydrocortisone in combination with dexamethasone in a glucocorticoid sensitive Bel1 
cell line. B. Cytotoxicity of hydrocortisone in combination with dexamethasone in a glucocorticoid sensitive 
MHH-CALL2 cell line. c. Cytotoxicity of hydrocortisone in combination with dexamethasone in a glucocorti-
coid resistant MHH-CALL4 cell line. d. Cytotoxicity of hydrocortisone in combination with dexamethasone 
in a glucocorticoid resistant Reh cell line. e. Hydrocortisone dose-response curve of glucocorticoid sensi-
tive (Bel1, MHH-CALL2) and 2 glucocorticoid resistant (MHH-CALL4, Reh) cell lines. 
Responsiveness of leukemic cell lines was determined by an 4-day total cell kill MTT-assay. The experiment 
was done twice for each of the 4 depicted cell lines. Sensitivity to dexamethasone was corrected for cell 
death induced by hydrocortisone as single agent to determine the synergistic or antagonistic effect of the 
drug combination. Data are presented as mean plus SEM.
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leukemic cell lines purchased from Deutsche Sammlung von Mikroorganismen und 
Zellkulturen (DSMZ, Braunschweig, Germany): Bel1 (MLL-AF4+, BCP-ALL), MHH-CALL2 
(hyperdiploid, BCP-ALL), MHH-CALL4 (B-other, BCP-ALL), Reh (ETV6-RUNX1+, BCP-ALL). 
An MTT-assay was used using previously reported conditions.9-11 MTT assays are suitable 
to test the sensitivity of leukemic cells for prednisolone and dexamethasone and these 
results are indicative for the prognosis of children with newly diagnosed ALL.1, 9, 10 MTT 
assays measure total cell kill, but do not reveal the underlying mechanism of cell death. 
We previously showed that prednisolone induces apoptosis in leukemic cells of patients 
as illustrated by a decrease in mitochondrial membrane potential, increased caspase 3 
cleavage and Annexin V positivity / propidium iodide negativity.12 Hydrocortisone (Bufa 
Pharmaceutical Products) induced cell death in the glucocorticoid sensitive cell lines 
Bel1 and MHH-CALL2, whereas it did not affect the viability of glucocorticoid resistant 
cell lines MHH-CALL4 and Reh (Figure 2E). In combination, hydrocortisone did not affect 
or even sensitized glucocorticoid sensitive cell lines to dexamethasone (Sigma) or pred-
nisolone (Bufa Pharmaceutical Products; Figure 2A-B and Figure S3C), whereas the level 
of resistance remained unaffected in resistant cell lines upon increasing concentrations 
of hydrocortisone (Figure 2C-D and Figure S3A-B). 
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Figure 3. Hydrocortisone does not induce resistance to glucocorticoids in patients’ leukemic cells taken at initial 
diagnosis.
An MTT-assay was used to determine the cytotoxic effect of hydrocortisone (3.6 ng/mL) in combination 
with dexamethasone (0.012 μg/mL) or prednisolone (0.061 μg/mL for sensitive patients and 0.49 μg/mL for 
resistant patients) in patients’ leukemic cells. Patients’ cells of different ALL subtypes were included (ETV6-
RUNX1+ B-ALL, B-other, hyperdiploid B-ALL, T-ALL). Statistical analysis was performed with a Mann-Whitney 
U test (**= p≤0.01, *= p≤0.05, ns = not significant). Data are presented as median and interquartile range. 
Sensitivity was corrected for cell death induced by hydrocortisone as single agent to determine the syner-
gistic or antagonistic effect of the drug combinations. Further details on the drug sensitivity of different ALL 
subtypes are described in the supplemental documents.
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Subsequently, we aimed to confirm these results in primary patients’ cells of different 
ALL subtypes (ETV6-RUNX1+, B-other, hyperdiploid and T-ALL). Hydrocortisone sensitized 
glucocorticoid sensitive patients’ cells to dexamethasone or prednisolone (Figure 3), 
including ETV6-RUNX1+ cells (Supplemental Figure S4-S5). Hydrocortisone did not affect 
the level of resistance to glucocorticoids of resistant patients’ leukemic cells. (Figure 3) 
Our in vitro studies show that addition of hydrocortisone does not interfere or even 
sensitizes ALL cells to glucocorticoids. The (sensitizing) effect of hydrocortisone is found 
for both types of glucocorticoids tested, i.e. dexamethasone and prednisolone. The 
expression level of the receptor for hydrocortisone, i.e. MR, is very low compared to the 
expression levels found for GR in leukemic patients’ cells. The MR levels were remarkable 
high in ETV6-RUNX1+ leukemic cells compared to other subtypes of ALL, for which an 
explanation is yet lacking. The higher MR levels in ETV6-RUNX1+ patients’ leukemic cells 
did not affect the response to hydrocortisone and glucocorticoids.
In conclusion, addition of hydrocortisone does not interfere with the response 
of leukemic cells to dexamethasone and prednisolone. Our next aim is to determine 
whether dexamethasone-induced neuropsychological side effects can be prevented 
by co-administration of hydrocortisone. To this aim, we have initiated a double-blinded 
randomized control trial in which we test the effect of physiological dosages of hy-
drocortisone during dexamethasone treatment on neuropsychological symptoms in 
children with newly diagnosed ALL (NTR3280). 
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SuPPLemenTAL FiGuReS
Cortisol 
Figure S1. Hypothesis. 
Dexamethasone treatment is known to deplete endogenous cortisol levels. This may cause the cerebral 
side-eff ects reported for this drug. Exogenous applied cortisol (hydrocortisone) may reduce these side-
eff ects through binding to the mineralocorticoid receptor for which dexamethasone has no affi  nity. GR = 
glucocorticoid receptor, MR = mineralocorticoid receptor.
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Figure S2. Correlation between microarray and RT-qPCR determined expression levels of MR and GR.
A. Correlation between microarray and RT-qPCR of MR, R=0.88, p<0.0001. B. Correlation between microar-
ray and RT-qPCR of GR, R=0.48, p=0.02. MR = mineralocorticoid receptor, GR = glucocorticoid receptor.
Spearman’s rank correlation coeffi  cient was calculated to compare microarray gene expression results to 
RT-qPCR results. 
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Figure S3. Hydrocortisone does not induce resistance to prednisolone in leukemic cell lines. 
A. Cytotoxicity of hydrocortisone in combination with prednisolone in a glucocorticoid resistant MHH-
CALL4 cell line. B. Cytotoxicity of hydrocortisone in combination with prednisolone in a glucocorticoid re-
sistant Reh cell line. c. Cytotoxicity of hydrocortisone in combination with prednisolone in a glucocorticoid 
sensitive MHH-CALL2 cell line. 
Responsiveness of leukemic cell lines was determined by an MTT-assay. Sensitivity to prednisolone was cor-
rected for cell death induced by hydrocortisone as single agent to determine the synergistic or antagonistic 
effect of the drug combination.
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Figure S6. Hydrocortisone does not induce more resistance to leukemic patients’ cells which are intrinsic resis-
tant to prednisolone in different subtypes of ALL. 
Effect of hydrocortisone (0 ng/ml, 0.36 ng/ml, 3.6 ng/ml, 36 ng/ml) on prednisolone sensitivity of gluco-
corticoid resistant primary patients’ cells (hyperdiploid, ETV6-RUNX1+, T-ALL, B-other). Data are presented 
as mean plus SEM. Responsiveness of leukemic cells was determined by an MTT-assay. The cell survival 
of prednisolone-exposed cells was corrected for cell death induced by hydrocortisone to determine the 
sensitizing effect of hydrocortisone.
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Figure S7. Hydrocortisone does not induce more resistance to leukemic patients’ cells which are intrinsic resis-
tant to dexamethasone in different subtypes of ALL. 
Effect of hydrocortisone (0 ng/ml, 0.36 ng/ml, 3.6 ng/ml, 36 ng/ml) on dexamethasone sensitivity of gluco-
corticoid resistant primary patients’ cells (hyperdiploid, ETV6-RUNX1+, T-ALL, B-other). Data are presented 
as mean plus SEM. Responsiveness of leukemic cells was determined by an MTT-assay. The cell survival of 
dexamethasone-exposed cells was corrected for cell death induced by hydrocortisone to determine the 
sensitizing effect of hydrocortisone.
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SuPPLemenTAL meThodS
methods microarrays
RNA was extracted by means of Trizol isolation (Invitrogen, Bleiswijk, Netherlands) according to the 
manufacturer’s protocol and RNA quality and integrity determined with the 2100 bioanalyzer (Agilent, 
Amstelveen, Netherlands). The Affymetrix One-Cycle cDNA Synthesis kit (Santa Clara, CA, USA) and the 
GeneChip IVT Labeling kit (Santa Clara, CA, USA) were used to synthesize cRNA. RNA processing and hybrid-
ization to the Affymetrix U133 Plus 2.0 GeneChip oligonucleotide microarray were performed according to 
the manufacturer’s protocol. Gene-expression values were calculated with Affymetrix Microarray Suite ver-
sion 5.0. Expression signals were scaled to the target intensity of 500 and log transformed. Only arrays with 
scaling factor <10 and GAPDH cRNA integrity (3’/5’) <3 were used for subsequent normalization procedures 
and analysis of GR and MR expression levels. Normalization of Affymetrix U133 Plus 2.0 data was performed 
by Robust Multichip Average and variance stabilization and normalization 2 (VSN2) in the R environment 
(Huber et al. Bioinformatics 2002). Probe sets 232431_at for GR and 205259_at for MR were used to deter-
mine the expression levels of both receptors in leukemic cells. 
methods RT-qPcR
RNA was extracted using Trizol isolation (Invitrogen), where after cDNA was synthesized according to stan-
dardized procedures. (Ariës, Leukemia 2014) NR3C1 (GR) and NR3C2 (MR) mRNA levels were quantified by in-
corporation of SYBR Green (Thermo Scientific) by RT-qPCR (Applied Biosystems 7900HT). Primers for NR3C1 
were; 5’-TGC-CAA-GGA-TCT-GGA-GAT-GA -3’ (forward) and 5’-TGG-GAG-GTG-GTC-CTG-TTG-T-3’ (reverse). 
Primers for NR3C2 were; 5’-TCC-CTT-CTG-CTA-TTG-TTG-3’ (forward) and 5’-TCC-CCa-CAC-ACC-AAA-CAT-
ATT-3’ (reverse). Primers used for the reference gene RPS20, were 5’-AAGGGCTGAGGATTTTTG-3’ (forward) 
and 5’-CGTTGCGGCTTGTTAG-3’ (reverse).
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Hydrocortisone as an intervention for 
dexamethasone-induced side effects in 
pediatric acute lymphoblastic leukemia 
patients: Results of a double blind randomized 
controlled trial
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ABSTRAcT
Purpose: Dexamethasone is a key component in treating pediatric acute lymphoblastic 
leukemia (ALL), but can induce serious side effects. Recent studies have led to the hy-
pothesis that neuropsychological side effects may be due to cortisol depletion of the 
cerebral mineralocorticoid receptors. We examined whether including a physiological 
dose of hydrocortisone in dexamethasone treatment can reduce neuropsychological 
and metabolic side effects in children with ALL. 
Patients and methods: We performed a multicenter double blind, randomized con-
trolled trial with a cross-over design. Fifty out of 116 potentially eligible patients (3-16 
years) were enrolled and were treated with two consecutive courses of dexamethasone 
in accordance with Dutch Childhood Oncology Group ALL protocols. The patients were 
randomly assigned to receive either hydrocortisone or placebo in a circadian rhythm (10 
mg/m2/day) during both dexamethasone courses. The primary outcome measure was 
the parent-reported Strength and Difficulties Questionnaire-Dut (SDQ), which assesses 
psychosocial problems. Other endpoint variables included questionnaires, neuropsy-
chological tests, and metabolic parameters.
Results: Of the 48 patients who completed both courses, hydrocortisone had no signifi-
cant effect on outcome. However, a more detailed analysis revealed that in 16 patients 
who developed clinically relevant psychosocial side effects, the addition of hydrocorti-
sone substantially reduced their SDQ scores in the following domains: Total Difficulties, 
Emotional Symptoms, Conduct Problems, and Impact of Difficulties. Moreover, in nine 
patients who developed clinically relevant sleep-related difficulties, the addition of 
hydrocortisone reduced Total Sleeping Problems and Disorders of Initiating and Main-
taining Sleep. In contrast, hydrocortisone had no effect on metabolic parameters.
conclusion: Our results suggest that adding a physiological dose of hydrocortisone to 
dexamethasone treatment can reduce the occurrence of serious neuropsychological 
side effects and sleep-related difficulties in pediatric ALL patients.
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RCT
inTRoducTion
Dexamethasone has high anti-leukemic activity and excellent penetration into the 
central nervous system; thus, dexamethasone is commonly included in the treatment 
of pediatric acute lymphoblastic leukemia (ALL).(1-4) Unfortunately, however, dexa-
methasone treatment can cause robust neuropsychological and metabolic side effects. 
The reported frequency of patients who develop dexamethasone-related side effects 
regarding mood, behavior, cognition, and sleep ranges from 5-75%.(5-10) Importantly, 
patients and their families report that these side effects are the most detrimental with 
respect to quality of life.(5-11) Because many current ALL treatment protocols call for 
pediatric ALL patients to receive pulses of dexamethasone for approximately one and 
a half years, these side effects can have a major impact on the child’s daily activities 
and development.(5, 9, 12) To date, only one intervention study has been performed 
to investigate glucocorticoid-induced neuropsychological side effects; this study found 
that chlorpromazine and lorazepam reduced glucocorticoid-related symptoms.(13) 
However, because these agents can induce other side effects, including drowsiness, 
orthostatic hypotension, and paradoxical agitation, they should therefore only be pre-
scribed for severe behavioral problems and/or psychosis.
Until recently, the pathophysiology of dexamethasone-related neuropsychological side 
effects was poorly understood.(7) For example, excessive activation of cerebral gluco-
corticoid receptors (GRs) by corticosteroid binding has been suggested to underlie the 
neuropsychological side effects.(7) However, recent data revealed that mineralocorti-
coid receptors (MRs) in the brain may play an even more important role in regulating 
mood, behavior, cognition, and sleep.(14, 15) In the human brain, GRs and MRs have 
similar expression patterns; however, these two receptor types have strikingly differ-
ent ligand affinities.(16) For example, dexamethasone has a 30-40 fold higher affinity 
for the GR than cortisol, whereas dexamethasone does not bind to the MR. In contrast, 
prednisolone binds the GR, but has a low affinity for the MR.(17) Finally, cortisol (i.e. 
hydrocortisone) can bind both receptor types, but has a higher affinity for the MR.(18) 
Both dexamethasone and prednisolone suppress the production of cortisol via a nega-
tive feedback loop acting on the hypothalamus-pituitary-adrenal axis.(17) However, 
prednisolone –but not dexamethasone- can bind and activate the MR; thus, patients 
treated with dexamethasone have fewer cortisol-bound MRs, which may lead to more 
side effects.(19) Data from animal studies and small case series suggest that the resulting 
dexamethasone-induced cortisol depletion of MRs in the brain causes or exacerbates 
the side effects with respect to mood, behavior, and/or cognition.(14, 15, 20, 21) 
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These key fi ndings led us to hypothesis that dexamethasone-induced cortisol depletion 
of the MR, may underlie the neuropsychological side eff ects in pediatric ALL patients.
(22) Thus, we examined whether these side eff ects can be reduced by adding physi-
ological dosages of hydrocortisone to dexamethasone treatment.(22) Importantly, we 
previously reported that hydrocortisone does not reduce dexamethasone sensitivity of 
ex vivo ALL patients’ cells.(22) Therefore, we performed a randomized controlled trial to 
determine whether including hydrocortisone in the dexamethasone treatment regimen 
reduces the neuropsychological, metabolic, and physical side eff ects in children with 
ALL. 
meThodS
Study design and participants
We performed a randomized, placebo-controlled, double blind trial with a crossover 
design (Figure 1). The primary objective of the study was the reduction of psychosocial 
problems during dexamethasone treatment. The secondary objective was to study 
the infl uence of hydrocortisone addition during dexamethasone treatment on sleep-
related diffi  culties, eating behavior, physical activity, cognitive functions, and metabolic 
parameters. Patients were recruited at fi ve Dutch pediatric oncology departments. ALL 
patients (3-16 years) treated according to the Dutch Childhood Oncology Group (DCOG) 
ALL-10 or ALL-11 medium risk protocols, including dexamethasone pulses during the 
maintenance phase (after asparaginase and anthracyclines were discontinued), were eli-
gible for inclusion. The following exclusion criteria were applied: a signifi cant language 
Randomization 
N=50 
Dexamethasone + 
Hydrocortisone 
Dexamethasone +  
Placebo 
Dexamethasone + 
Hydrocortisone 
Dexamethasone +  
Placebo 
Study course 1 
Treatment days 
Group 2 
N=25 
Group 1 
N=25 
Study course 2 
Testing days 
1           2           3            4          5 1         2            3           4          5 
1                                                    2 3                                                  4                              
Group 1 
N=23 
Group 2 
N=23 
Figure 1. Study design. 
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barrier; evidence of pre-existing intellectual disability; and any condition that could 
have interfered with the administration and/or absorption of the study medication and/
or dexamethasone. Parents and legal guardians of patients provided written informed 
consent; patients 12-16 years of age also provided their own written informed consent.
The part of maintenance phase in which the intervention was conducted, consists of 
19 consecutive treatment cycles lasting 21 days each, in which patients receive five 
consecutive days of dexamethasone treatment, vincristine once (first day of the cycle), 
6-mercaptopurine daily and methotrexate once per week. The study included two 5-day 
courses of dexamethasone (6mg/m2/day: 3 doses containing 2 mg/m2 each) in which 
each patient also received either placebo or hydrocortisone; in this cross-over study, 
patients who were randomized to receive hydrocortisone in the first course received 
placebo in the second course, and vice versa (Figure 1). The median start of the study 
was in the fourth cycle after stop of asparaginase. The median time between the two 
5-day study courses was 3.0 weeks (Inter Quartile Range (IQR): 3.0, 6.0) or one cycle. 
The daily dose of hydrocortisone was administered orally in three doses (containing 5, 
3, and 2 mg/m2) at the same time as dexamethasone, and was designed to follow the 
normal circadian rhythm. Placebo was administered in a similar dose and scheme as hy-
drocortisone. A washout period of ≥16 days was included between the dexamethasone 
treatment courses. 
Procedures
The primary endpoint was the “Total Difficulties” score from the parent-reported 
Strengths and Difficulties Questionnaire in Dutch (SDQ-Dut). (Table S1) The secondary 
endpoints were obtained from additional questionnaires, neuropsychological tests (see 
Table S1 and Supplemental), and metabolic parameters. In each course, mood, behavior, 
cognition, and sleep were assessed on the morning of treatment day 1 (i.e., before the 
start of dexamethasone treatment) and the morning of treatment day 5 (i.e., after four 
full days of dexamethasone treatment). 
Questionnaires
The parent-reported SDQ-Dut, which assesses psychosocial difficulties and strengths, 
has been validated in the Dutch population. The SDQ-Dut(23-26) is a brief questionnaire 
that assesses the psychosocial functioning of children and adolescents (3-16 years of 
age) by either parent reporting or self-reporting (patients 11-16 years of age). The ques-
tionnaire contains 25 items in the following five subscales (see Supplemental for score 
ranges): Emotional Symptoms, Conduct Problems, Hyperactivity and Inattention, Peer 
Relationship Problems and Prosocial Behavior. The Total Difficulties score, defined as the 
sum of the first four subscale scores (i.e., excluding Prosocial Behavior) was calculated. 
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The impact of these difficulties on the child’s life was measured using the Impact of 
stress score. A higher SDQ Total Difficulties score reflects more problems. Ideally, both 
parents and all patients ≥11 years of age completed the SDQ-Dut on all four testing days. 
On each testing day, the participants were instructed to provide information regarding 
psychosocial problems experienced in the previous four days. The SDQ scores obtained 
from the primary parent (defined as the parent who was present in the outpatient clinic 
at all four testing days) were used for all analyses; in the majority of cases, the primary 
parent was the patient’s mother.
The Sleep Disturbance Scale for Children (SDSC)(27) was used to assess sleep quality 
and sleep disturbances in the patients. The SDSC has a combined score that covers 
the six most common sleep disorders experienced during childhood; these disorders 
are Disorders of Initiating and Maintaining Sleep (DIMS), Sleep Breathing Disorders 
(SBD), Disorders of Arousal (DA), Sleep-Wake Transition Disorders (SWTD), Disorders of 
Excessive Somnolence (DES), and Sleep Hyperhidrosis (SHY). A higher score reflects the 
presence of more problems.
The Dutch Eating Behavior Questionnaire for children (DEBQ-C)(28) has three subscales: 
Restrained Eating, Emotional Eating, and External Eating; a higher score on each sub-
scale reflects the presence of more problems. 
The daily physical activity was measured using the Baecke Physical Activity Question-
naire(29)(BPAQ), which consists of 16 questions organized in three sections: school 
activity, sports activity, and leisure activity. With the BPAQ, a higher score on each scale 
reflects higher activity.
Neuropsychological assessment
Neuropsychological tests designed for children and young adults were used to assess 
skills in four domains (memory, attention, visual-spatial functions, and processing 
speed; Table S1). The neuropsychological tests were performed by the same investigator 
(author LW) on all four testing days. 
Physical parameters, anthropometric measurements and laboratory tests
Parents and children were instructed to maintain a diary of the child’s dietary activ-
ity during the first four treatment days in each study courses. (Supplemental) Height 
(meters), weight (kg), waist-hip circumference (cm) and blood pressure (mmHg) were 
measured on all four testing days. 
Physical activity was measured throughout both courses using a Philips DirectLife 
activity monitor.(30) Fasting blood samples (whole blood) were taken between 8am 
57
RCT
and 10am and used to analyze lipid profiles (triglycerides, cholesterol, HDL, and LDL), 
glucose and insulin levels. 
Adverse events
Adverse events (i.e., any adverse change in condition between the first dose and 16 days 
after the last dose) were assessed in accordance with the US National Cancer Institute’s 
Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.(31) 
Statistical analysis
The data were analyzed for carry-over effects and for period (i.e., order of treatment) 
effects using the paired Student’s t-test (each patient served as his/her own control).
(32) In each treatment course, a delta-score (i.e., the difference between two scores) 
was calculated by subtracting the score on treatment day 1 from the score on treatment 
day 5. The treatment effect was assessed by comparing the delta-placebo score with 
the delta-hydrocortisone score using the paired Student’s t-test (normally distributed 
values) or the Wilcoxon-signed-rank test. Adjusted P-values (Benjamin-Hochberg proce-
dure) are reported in Table S8. A nested subset analysis was used to evaluate the effect of 
hydrocortisone in children who experienced clinically relevant dexamethasone-related 
side effects. Clinically relevant psychosocial side effects were defined as a change in 
parent-reported SDQ Total Difficulties score of ≥5 during the patient’s respective placebo 
course; this difference represents approximately one standard deviation in the general 
population(23). Clinically relevant sleeping problems were defined as a change in the 
Total SDSC score ≥7 (one standard deviation) during the patient’s respective placebo 
course.(27, 33) In the subset analysis, we examined the effect size rather than the P-value 
because of the potential influence of regression to the mean in the subgroup selection.
ReSuLTS
enrollment
During the recruitment period, 50 out of 116 potentially eligible patients (49.5%) enrolled 
at the five pediatric oncology departments from July 2012 through February 2015. The 
most frequently cited reasons for not participating in the study were the high burden of 
two extra visits (37 patients) and an absence of a priori dexamethasone-related side ef-
fects (8 patients). (Figure 2) After the patients were randomly assigned to the treatment 
groups, two patients left the trial after the first course due to dexamethasone-related 
osteonecrosis; these patients were excluded from the efficacy analyses. 
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The treatment groups were similar with respect to age, type of leukemia, treatment 
protocol, and central nervous system status at diagnosis. (Table S2) Two patients did not 
complete the parent-reported SDQs at all four time points and were therefore excluded 
from the effi  cacy analysis. Four patients developed serious adverse events after the 
fi rst study course (2 hydrocortisone courses; 2 placebo courses); three of these patients 
developed febrile neutropenia (grade 2-3), and one patient developed osteomyelitis 
(grade 3). These serious adverse events were not considered related to study medication, 
and all four patients remained in the study. The adverse events were similar between the 
hydrocortisone and placebo courses, indicating that no hydrocortisone-specifi c adverse 
events were observed. (Table S3) No carry-over eff ect (P=0.34; independent samples 
Student’s t-test) or period eff ect (P=0.76; Mann-Whitney test) was observed based on 
the primary outcome.
Psychosocial problems
The SDQs results obtained from 46 primary parents (41 mothers and 5 fathers) were 
analyzed in order to evaluate the psychosocial problems of the children. Four days of 
dexamethasone treatment signifi cantly increased the patients’ problems as reported by 
all SDQ scales and subscales. In 30 of the 46 patients (65%), dexamethasone induced 
an increase in psychosocial problems (defi ned as a change in the SDQ Total diffi  culties 
116 screened patients 
50 patients enrolled 
15 excluded: 
-  discontinuation of dexamethasone (4) 
-  hydrocortisone stress dose (4) 
-  too many toxicities (2) 
-  left for treatment abroad (2) 
-  language barrier (2) 
-  died after screening (1) 
Group 1 
25 randomly assigned to: 
Course 1: hydrocortisone 
Course 2: placebo 
Group 2 
25 randomly assigned to: 
Course 1: placebo 
Course 2: hydrocortisone 
25 completed 2 study 
courses 
23 assessed for primary 
endpoint 
101 eligible patients  
51 refusals: 
-  burden too high (38) 
-  no side eﬀects of dexamethasone (8) 
-  no participation in studies (3) 
-  refuse to drink oral solutions (2) 
23 completed 2 study 
courses 
2 discontinued after course 1 
(stop of  dexamethasone) 
23 assessed for primary 
endpoint 
2 incomplete for 
SDQ analysis 
Figure 2. Patient eligibility and randomization. 
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score of ≥1) during the placebo course. One third of the population did not have any 
increase in SDQ Total difficulties on dexamethasone. The median SDQ “Total difficulties” 
score of the entire study group on treatment day 5 in the placebo course was 9.5, which 
is within the normal range. 
In the entire group, addition of hydrocortisone did not affect the “Total difficulties” 
score (mean difference was -0.8±5.5; P=0.33), “Emotional symptoms” (mean difference 
was -0.6± 2.3; P=0.08), “Conduct problems” (mean difference was 0.0±1.5; P=1.00) or the 
other SDQ subscales compared to the placebo course. (Figure 3) 
However, when we examined the effect of hydrocortisone on the subset of 16 patients 
who had clinically relevant dexamethasone-related side effects (i.e., an increase in 
their SDQ “Total difficulties” score≥5), we found that hydrocortisone had a clinically 
significant treatment effect. In these 16 children hydrocortisone had a clear effect on 
the “Total difficulties” delta-score compared to placebo (the median difference was -5.0; 
Inter Quartile Range (IQR): -7.8 to -3.0) (Figure 4). In five of these 16 patients (31%) the 
“Total difficulties” score decreased from a high score in the placebo course to a score in 
the normal range with the addition of hydrocortisone. We also observed a significant 
effect of hydrocortisone versus placebo on “Emotional symptoms” (median difference 
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Figure 3. The effect of hydrocortisone addition in the total group (N=46)(left bars with no pattern) and in the pa-
tients (N=16)(right bars with pattern) with clinically relevant dexamethasone-induced psychosocial side effects 
on SDQ subscales. Effect was measured by: delta hydrocortisone minus delta placebo. Delta = score treatment 
day 5 minus score treatment day 1. Box-Whisker plots with median and 5-95 percentiles are depicted for each 
SDQ scale. A negative score reflects a decrease in side effects by hydrocortisone, with exception of the Prosocial 
Behavior score (positive score reflects less side effects). 
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was -1.5; IQR: -4.0 to -1.0), “Conduct problems” (median difference was -1.0; IQR: -2.0 to 
0.0), and “Impact of stress” (median difference was -1.0; IQR: -2.0 to 0.0) (Figure 4). (See 
Table S4-5 for real SDQ scores and for point estimates (95% confidence intervals) of the 
median differences)
With respect to their baseline characteristics, the patient group with clinically relevant 
dexamethasone-induced side effects did not differ significantly from the group of pa-
tients without clinically relevant dexamethasone-induced psychosocial side effects. The 
week of maintenance phase in which the patients participated did not influence the side 
effects. (P=0.47) The child-reported SDQ scores (N=10) did not differ significantly from 
their respective parent-reported scores (P=0.44).
Sleep
The parents of 47 children completed the SDSC questionnaire on all four testing days. 
Dexamethasone treatment alone (i.e., the placebo course) significantly increased the 
DA (P=0.04), SWTD (P=0.01) and DES (P=0.01) scores. In the entire patient group, hydro-
cortisone had no significant effect on the SDSC scores (SDSC Total score: P=0.84, DIMS: 
P=0.74, DES: P=0.29, SWTD: P=0.29). (Figure 5) However, when the 9 children (19%) who 
had clinically relevant dexamethasone-induced sleeping problems (defined as a change 
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Figure 4. The effect of hydrocortisone addition in the total group (N=47) (left bars with no pattern) and in the 
patients (N=9) (right bars with pattern) that suffer from clinically relevant dexamethasone-related sleeping 
problems on the SDSC subscales. Effect was measured by: delta hydrocortisone minus delta placebo. Delta= 
score treatment day 5 minus score treatment day 1. Box-Whisker plots with median and 5-95 percentiles are 
depicted for each SDSC scale. A negative score reflects a decrease in side effects by hydrocortisone. 
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in SDSC Total score≥7 during the placebo course) were analyzed separately, hydrocorti-
sone reduced both the SDSC Total scores (median difference was -11.0; IQR: -16.0 to 0.0) 
and DIMS scores (median difference was -3.0; IQR: -7.0 to -0.5) (Figure 6). The majority of 
patients with clinically relevant sleeping problems also experienced clinically relevant 
psychosocial side effects during dexamethasone (N=7, 78%).
neuropsychological functioning
Neuropsychological tests revealed that dexamethasone treatment alone had no effect 
on attention (auditory attention, response set, and inhibition), visual-spatial functions 
(design copying), memory (narrative memory and memory for designs) or processing 
speed. However, the addition of hydrocortisone significantly improved long-term visual 
memory (MDDT; P=0.01,N=47) (Table S4); hydrocortisone had no effect on the other 
neuropsychological tests of attention, visual-spatial function (NEPSY), or processing 
speed (Wechsler). (Table S6) The neuropsychological performance of the children with 
clinically relevant dexamethasone-induced psychosocial side effects was similar with 
the neuropsychological performance of the entire group. 
metabolism
Physical activity data (measured using the BPAQ) were available for 36 patients, and ac-
tivity monitor data were available for 41 patients. Physical activity was neither affected 
by dexamethasone, nor by hydrocortisone addition. 
Dietary intake and data regarding eating behavior (measured using the DEBQ-C) were 
available for 44 and 17 patients, respectively (Table S1). Hydrocortisone had no significant 
effect on energy intake (P=0.88). Similarly, including hydrocortisone had no significant ef-
fect on weight, height, waist/hip ratio, blood pressure, or any laboratory values (Table S7). 
diScuSSion
Here, we report the results of the first randomized controlled clinical trial to investigate 
whether a potentially safe intervention (i.e., physiological doses of hydrocortisone) can 
be used to reduce dexamethasone-induced neuropsychological side effects in pediatric 
ALL patients. Both patients and their parents consider neuropsychological side effects to 
be the most detrimental consequences of ALL treatment with respect to reducing quality 
of life.2 Our results show that although hydrocortisone had no significant beneficial ef-
fect in the entire patient group, hydrocortisone significantly decreased dexamethasone-
related behavioral difficulties, emotional disorders, and sleep problems specifically in 
patients who experienced the most severe neuropsychological side effects. This finding 
is particularly relevant, as psychosocial problems can be present in up to two-thirds of 
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children with ALL, and half of the problems can be categorized as “clinically relevant”. 
Thus, our results indicate that these emotional and behavioral problems can be reduced 
in these children, thereby markedly improving quality of life.(34) Moreover, sleeping 
problems –half of which were categorized as “clinically relevant”- have been reported 
in 43% of patients, and reducing these problems may also improve quality of life.(35) 
The flipside of these findings is, that adding hydrocortisone does not benefit all children 
with ALL. One third of the population did not have any neuropsychological side effects 
on dexamethasone. This patient variability on side effects may be explained by genet-
ics(36), glucocorticoid sensitivity39 or dexamethasone clearance (higher drug levels)(37). 
The occurrence of neuropsychological side effects was independent of age, in contrast 
to Mrakotsky et al. who reported more neurobehavioral problems in younger children.
(38) It needs to be mentioned that subgroups are small and that regression to the mean 
could have influenced our subgroup selection and that our results should be confirmed 
preferably in a validation study in selected patients with symptoms only. However, 
the substantial effect size of the intervention indicates a benefit of hydrocortisone in 
patients with psychosocial problems and sleeping problems.
Hydrocortisone addition did improve one specific memory score; due to the absence of 
acute dexamethasone-induced impairment on cognitive function, the clinical relevance 
of this finding is limited. The absence of dexamethasone-induced short-term cognitive 
impairment is in accordance with the study of Wingenfeld et al(39) who did not find an 
effect of high-dose dexamethasone on working memory in healthy volunteers. 
Interestingly, hydrocortisone also had no effect on the metabolic side effects of 
dexamethasone. This lack of efficacy may be caused by a different pathophysiology of 
metabolic side effects. This notion is supported by the absence of a significant difference 
in body weight change during induction therapy -an important metabolic side effect of 
high dose glucocorticoids (e.g., prednisolone)- between children with neuropsychologi-
cal side effects and children without neuropsychological side effects. It is also conceiv-
able that metabolic side effects are not caused by cortisol depletion of the cerebral MRs.
In conclusion, the current study suggests that including a physiological dose of hydro-
cortisone decreases clinically relevant dexamethasone-induced psychosocial problems 
and sleeping problems in pediatric ALL patients. For a validation study it is important 
to identify these patients that benefit from hydrocortisone using the SDQ-Dut and the 
SDSC. Physiological doses of hydrocortisone are relatively inexpensive, provide a natu-
rally occurring hormone, and have no apparent negative effects. This novel yet simple 
intervention has the potential to significantly reduce neuropsychological side effects in 
patients receiving high-dose dexamethasone treatment.
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SuPPLemenTAL TABLeS.
neuropsychological assessment
Table S1. Overview of questionnaires and neuropsychological tests and the corresponding subjects who com-
pleted or performed the test.
Questionnaire / Test completed by:
SDQ-Dut parent Parent (child 3-16 yrs)
SDQ-Dut child Children 11-16 yrs
SDSC Parent (child 3-16 yrs)
DEBQ-C Children 7-12 yrs
BPAQ Parent (child 3-11 yrs)
Children 12-16 yrs
NEPSY AA Children 5-16 yrs
NEPSY RS Children 7-16 yrs
NEPSY INE Children 5-16 yrs
NEPSY DC Children 3-16 yrs
NEPSY NM Children 3-16 yrs
NEPSY MDT Children 3-16 yrs
NEPSY MDT delayed Children 5-16 yrs
Wechsler WPPSI III Children 3-6 yrs
Wechsler WISC III Children 7-16 yrs
Baseline characteristics
Table S2. Baseline characteristics of the enrolled patients (N=50). 
Group 1: 
hydrocortisone-Placebo 
n=25
Group 2: 
Placebo-hydrocortisone
n=25
P-value
Age at assessment (y) 9.0 (5.5-12.0) 5.0 (3.5-7.0) 0.09
Sex
female 13 (52) 14 (56) 0.78
male 12 (48) 11 (44)
Week of maintenance phase 34.0 (31.0-42.0) 40.0 (34.0-49.5) 0.15
ALL subtype 1.00
B-ALL 23 (92) 23 (92)
T-ALL 2 (8) 2 (8)
CNS status at diagnosis 0.57
CNS-1 12 (48) 10 (40)
CNS-2 13 (52) 15 (60)
CNS-3 0 (0) 0 (0)
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Data are shown as median (inter quartile range) or as number (%). CNS = central nervous system. CNS 1 = ≤ 
5 WBC/μl  and central nervous system fluid (CSF) with ≤ 1 leukemic cells, CNS 2 = ≤ 5 WBC/μl and CSF with ≥ 2 
identifiable leukemic cells, CNS 3 = > 5 WBC/μl  and CSF with identifiable leukemic cells.
Table S3. Adverse events according to the NCI CTCAE version 4.033 after 4 full days of hydrocortisone or placebo 
administration. N=48. Data are depicted as number (%). 
Hydrocortisone day 5 Placebo day 5 P-value
Cushingoid grade 1 10 (21) 12 (25) 0.16
Abdominal pain grade 1 7 (15) 5 (10) 0.42
Agitation grade 1 5 (10) 2 (4) 0.53
grade 2 2 (4) 1 (2) 
grade 3 0 (0) 1 (2) 
Nausea grade 1 1 (2) 3 (6) 0.32
Constipation grade 1 3 (6) 3 (6) 0.49
grade 2 2 (4) 1 (2) 
Diarrhea grade 1 1 (2) 0 (0) 0.32
Skin rash 0 (0) 1 (2) 0.32
Sensible neuropathy 0 (0) 1 (2) 0.32
Pain grade 1 5 (10) 5 (10) 1.00
Tiredness grade 1 22 (46) 16 (33) 0.74
grade 2 8 (17) 10 (21) 
grade 3 1 (2) 1 (2) 
Grade 1 = mild; intervention not indicated. Grade 2 = moderate; local or non-invasive intervention indicated. 
Grade 3 = severe or medically significant but not immediately life-threatening; hospitalization or prolongation 
of hospitalization indicated. 
The difference between the hydrocortisone and placebo course was tested with use of a Paired T-test.
Table S4. Overview of parent-reported SDQ scores (Median (Inter Quartile Range)) of patients with delta-SDQ 
overall stress≥5 in the placebo course (N=16).  More dexamethasone-induced problems is reflected by a higher 
delta score, except for ‘Prosocial behavior’ which becomes lower. 
Hydrocortisone
day1
Hydrocortisone
day5
Placebo 
day1
Placebo 
day5
Total difficulties 7.5 (4.5, 11.8) 12.5 (9.3, 16.8) 7.0 (4.3,11.0) 17.0 (12.3, 24.3)
emotional symptoms 2.0 (1.3, 5.0) 5.5 (2.0, 6.8) 2.5 (1.0, 4.0) 6.0 (4.0, 8.8)
conduct problems 1.0 (0.0, 3.8) 3.0 (1.0, 4.0) 1.0 (0.0, 3.0) 3.5 (2.3, 4.0)
hyperactivity and inattention 3.0 (1.0, 4.8) 3.5 (3.0, 5.0) 3.0 (0.3, 4.8) 5.0 (3.0, 6.8)
Peer relationship Problems 1.0 (0.3, 1.8) 2.0 (1.0, 2.8) 1.0 (0.0, 1.8) 3.0 (1.0, 4.0)
Prosocial behavior 7.5 (6.0, 9.0) 4.5 (3.0, 7.0) 7.5 (6.3, 9.8) 4.0 (3.0, 6.0)
impact of stress 0.0 (0.0, 1.8) 2.5 (1.0, 4.8) 0.0 (0.0, 3.5) 4.0 (2.3, 6.8)
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Table S5. The point estimates of the median differences and their Binomial-based 95% confidence intervals of 
parent-reported SDQ scores of patients with delta-SDQ overall stress≥5 in the placebo course (N=16) and par-
ent-reported SDSC-scores of patients with delta-SDSC total score ≥7 during the placebo course (N=9).
Point estimate median difference 95% confidence interval
Parent-reported SdQ-scores
Total difficulties -5.0 -8.0, -3.0
emotional symptoms -1.5 -4.0, -1.0
conduct problems -1.0 -2.0, 0.0
hyperactivity and inattention -1.5 -3.0, 1.0
Peer relationship Problems -0.5 -3.0, 1.0
Prosocial behavior 1.5 -1.0, 4.0
impact of stress -1.0 -2.0, 0.0
Parent-reported SdSc-scores   
SdSc Total -11 -17, 1 
dimS -3 -8, 2 
SBd 0 -2, 2 
dA 0 -1, 1 
SWTd 0 -1, 0 
deS -4 -10, 1 
ShY -1 -2, 0 
DIMS = Disorders of Initiating and Maintaining Sleep, SBD = Sleep Breathing Disorders, DA = Disorders of Arousal, 
SWTD = Sleep-Wake Transition Disorders, DES =  Disorders of Excessive Somnolence, SHY = Sleep Hyperhidrosis.
neurocognitive function
Table S6. Effect of hydrocortisone on neurocognitive test scores (Median (IQR)) of the total study group. 
Effect of hydrocortisone P-value
AA (N=32) 0.0 (-2.0, 0.8) 0.25
RS (N=21) 1.0 (-0.5, 2.0) 0.16
ine (N=30) -1.0 (-2.0, 4.0) 0.79
dc general (N=48) 0.0 (-1.0, 1.8) 0.71
dcPT (N=48) 0.0 (-8.8, 5.8) 0.79
nmFc (N=41) 1.0 (-4.0, 5.0) 0.63
nmRG (N=47) 0.0 (-1.0, 1.0) 0.90
mdT (N=47) 0.0 (-3.0, 6.0) 0.52
mddT (N=30) 0.0 (0.0, 3.0) 0.01
PSi (N=38) 0.0 (-6.8, 8.3) 0.92 
AA= auditory attention total correct, RS= response set total correct, INE= inhibition total errors, DC general= de-
sign copying total score, DCPT= design copying process total score, NMFC= narrative memory free and cued re-
call total score, NMRG= narrative memory recognition total score, MDT= memory for designs total score, MDDT= 
memory for designs delayed total score, PSI= Processing Speed Index.
Effect of hydrocortisone was measured by: delta hydrocortisone minus delta placebo. Delta score= score treat-
ment day 5 minus score treatment day 1. N varies due to differences in validation for age. The treatment effect 
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of hydrocortisone was tested by comparing delta hydrocortisone with delta placebo with a Wilcoxon Signed 
Rank test.
Laboratory parameters
Table S7. Effect of hydrocortisone on HDL, LDL, total cholesterol, insulin, glucose and triglycerides levels (Median 
(IQR)). Effect of hydrocortisone was measured by: delta hydrocortisone minus delta placebo. Delta score = score 
treatment day 5 minus score treatment day 1. The treatment effect of hydrocortisone was tested by comparing 
delta hydrocortisone with delta placebo with a Wilcoxon Signed Rank test.
Effect of hydrocortisone P-value
hdL 0.03 (-0.25, 0.18) 0.93
LdL -0.05 (-0.32, 0.34) 0.55
Total cholesterol -0.20 (-0.35, 0.30) 0.43
insulin -13.10 (-263.65, 94.25) 0.53
Glucose -0.10 (-0.40, 0.78) 0.70
Triglycerides -0.07 (-0.38, 0.31) 0.27
Table S8. Benjamin-Hochberg adjusted P-values for multiple testing.
Tested hypothesis P-value Adjusted P-value
SdQ: hydrocortisone versus placebo
Total difficulties 0.33 0.58
Emotional symptoms 0.08 0.22
Conduct problems 1.00 1.00
influence week maintenance on SdQ Total difficulties 0.47 0.66
SdQ Total difficulties child versus to parent-report 0.44 0.66
SdSc: placebo course day 1 versus day 5
DA 0.04 0.14
SWTD 0.01 0.047
DES 0.01 0.047 
SdSc: delta hydrocortisone versus placebo   
Total score 0.84 0.95 
DIMS 0.74 0.94 
DES 0.29 0.58 
SWTD 0.29 0.58 
nePSY visual memory: delta hydrocortisone versus 
placebo 
0.01 0.047 
energy intake: hydrocortisone versus placebo 0.88 0.95 
DIMS = Disorders of Initiating and Maintaining Sleep, DA = Disorders of Arousal, SWTD = Sleep-Wake Transition 
Disorders, DES = Disorders of Excessive Somnolence.
Chapter 4
70
SuPPLemenTAL meThodS.
Study Randomization
Patients were recruited at five Dutch pediatric oncology departments: Erasmus Medical 
Center, Academic Medical Center Amsterdam, VU Medical Center, University Medical 
Center Utrecht and University Medical Center Groningen.
Subjects were registered via a web-based service called TenALEA, which generated 
subject numbers. The order in which the patients received placebo and hydrocortisone 
(Figure 1) was determined randomly and provided by a statistician. The personnel, 
participants, and clinicians were blinded with respect to the treatment allocation, with 
the exception of the pharmacy personnel at the participating centers, who had access 
to the randomization list. Blinding was maintained until the last patient’s final visit and 
after final validation of the online OpenClinica Community edition database.
Power analysis
A power analysis was performed on the primary outcome parameter (the Total difficul-
ties score of the parent-reported Strengths and Difficulties Questionnaire in Dutch). The 
inclusion of ≥40 children was determined to be sufficient to achieve >80% probability 
of detecting a significant effect (α = 0,05) of the intervention based on a change of 6 
points (±1 standard deviation) in the Total Difficulties score. Based on the probability of 
patients dropping out of the study (20%), we determined that 50 patients were required 
for this study.
ethics committee
The study protocol was approved by the local ethics committee at each participating cen-
ter (MEC-2012-155/ EudraCT 2011-003815-46). In accordance with national regulations, 
parents and legal guardians of patients provided written informed consent; patients 
12-16 years of age also provided their own written informed consent. The study was 
performed in accordance with the Declaration of Helsinki and followed the principles of 
good clinical practice. (WHO guidelines Good Clinical Practice for trials with pharmaceuti-
cal products. 1995) The study was registered in the Dutch Trial Registry (NTR3280).
Strengths and difficulties Questionnaire (SdQ)
The questionnaire contains 25 items in the following five subscales: Emotional Symp-
toms (normal: 0-3, mildly elevated: 4, high: 5-10); Conduct Problems (normal: 0-2, mildly 
elevated: 3, high: 4-10), Hyperactivity and Inattention (normal: 0-2, mildly elevated: 3, 
high: 4-10), Peer Relationship Problems (normal: 0-5, mildly elevated: 6, high: 7-10) and 
Prosocial Behavior (normal: 6-10, mildly elevated: 5, high: 0-4). A Total Difficulties score 
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(normal range: 0-10, mildly elevated: 11-13, high: 14-40) was calculated by summing the 
first four subscale scores (i.e., excluding Prosocial Behavior).
Sleeping disturbance Scale for children (SdSc)
The parent-reported SDSC has been validated for use in children 6-16 years of age; in ad-
dition, a pilot study performed in Italy found that the SDSC can also be used for children 
3-6 years of age. (Romeo DM, Bruni O, Brogna C, et al: Application of the sleep disturbance 
scale for children (SDSC) in preschool age. Eur J Paediatr Neurol 17:374-382, 2013) We there-
fore used the SDSC for our entire study population. The total SDSC score is the sum of 
the 26 included items (on a Likert scale) with a range of 26 -130.
dutch eating Behavior Questionnaire (deBQ)
The DEBQ-C has been validated for use in children 7-12 years of age and was therefore 
completed by patients 7-12 years of age. 
Baecke Physical Activity Questionnaire (BPAQ)
The questions in each section are scored on a 5-point Likert scale. Although the 
BPAQ has been validated for use only in children 12 years of age and older (Vogels N, 
Westerterp-Plantenga MS: Categorical strategies based on subject characteristics of dietary 
restraint and physical activity, for weight maintenance. Int J Obes (Lond) 29:849-857, 2005) 
it has also been used before as a parent-reported questionnaire for children of 3-9 years 
of age. (Kaspiris A, Zaphiropoulou C, Vasiliadis E: Range of variation of genu valgum and 
association with anthropometric characteristics and physical activity: comparison between 
children aged 3-9 years. J Pediatr Orthop B 22:296-305, 2013) Therefore, in our study the 
BPAQ was completed by the parents of children 3-11 years of age and by children 12-16 
years of age.
neuropsychological assessment
Memory (Narrative memory (NMFC and NMRG) and Memory for Designs (MDT and 
MDDT)), attention (Inhibition (INE), Auditory Attention (AA), and Response Set (RS)), and 
visual-spatial functions (Design Copying (DC general and DCPT)) were assessed using 
NEPSY. Processing speed was assessed using the Processing Speed Index (PSI) of the 
age-appropriated Dutch version of the Wechsler scales (WPPSI-III for children 3-6 years 
of age and WISC-III for children 7-16 years of age).
Physical parameters, anthropometric measurements and laboratory tests
Parents and children were instructed to maintain a diary of the child’s dietary activity 
during the first four treatment days in each study courses. Food intake was converted to 
energy intake (in kcals) using a database of the chemical composition of foods (NEVO, 
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Netherlands Food Composition chart, 2011). Height (in meters), weight (in kg), waist-hip 
circumference (in cm) and blood pressure (in mmHg) were measured on all four test-
ing days. Weight at diagnosis and at day 30 of induction therapy were retrospectively 
collected from patient records. Blood pressure was measured in the right arm using a 
Dinamap Procare with the subject in the sitting position after one hour’s of rest. 
Physical activity was measured throughout both courses using a Philips DirectLife 
activity monitor. Fasting blood samples (whole blood) were taken between 8 am and 
10 am and used to analyse lipid profiles (triglycerides, cholesterol, HDL, and LDL), glu-
cose and insulin levels. The fasting blood samples were centrifuged and kept frozen at 
−80°C until analysis as a batch at the end of the study. Serum samples were measured 
in the same laboratory using an enzymatic in vitro assay (Roche Diagnostics, Mannheim, 
Germany).
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ABSTRAcT
Dexamethasone, a highly effective drug in the treatment of pediatric acute lymphoblastic 
leukemia (ALL), can induce serious metabolic side effects. Since data are limited to small 
studies, we prospectively studied the direct effects of dexamethasone administration 
on all components of the metabolic syndrome (MetS) in ALL patients, and investigated 
whether these side effects were dependent on dexamethasone levels.
Fifty ALL patients (3-16 years of age) were included, and were studied during one 
5-days dexamethasone course in the maintenance phase of the Dutch Childhood Oncol-
ogy Group ALL-10 and ALL-11 protocol. Fasting insulin, glucose, total cholesterol, HDL, 
LDL, triglycerides levels, and anthropometric parameters were measured at baseline 
before start of dexamethasone (T1), and at day 5 (T2). Dexamethasone trough levels 
were measured at T2.
Dexamethasone administration significantly increased median fasting serum levels 
of HDL (1.42 versus 1.55 mmol/L, P=0.00), LDL (2.55 versus 2.76 mmol/L, P=0.00), total 
cholesterol (4.20 versus 4.60 mmol/L, P=0.00), triglycerides (0.86 versus 1.09 mmol/L, 
P=0.04), glucose (4.4 versus 4.7 mmol/L, P=0.00) and insulin (25.2 versus 216.5 pmol/L, 
P=0.00). Insulin resistance (HOMA-IR>3.4) increased from 8% to 85% (P=0.00). Dexa-
methasone also significantly increased diastolic and systolic blood pressure SDS. Dexa-
methasone trough levels (N=24) were positively correlated with high glucose levels at 
T2, but not with other parameters.
We conclude that dexamethasone induces metabolic toxicity on three components 
of the MetS, already within four days of treatment. These findings, together with the 
weight gain during dexamethasone treatment, may contribute to the higher prevalence 
of MetS and cardiovascular risk childhood leukemia survivors.
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inTRoducTion
Glucocorticoids are an important component of effective pediatric acute lymphoblastic 
leukemia (ALL) treatment.1 Unfortunately, high dose dexamethasone used in ALL treat-
ment is notorious for serious side effects.2, 3 Acute metabolic side effects are more appar-
ent in dexamethasone-based than in prednisone-based schedules.4, 5
Metabolic side effects, such as weight gain, altered fat distribution, hypertension, 
hyperglycemia, dyslipidemia, and altered insulin resistance have been described in 
10-45% of children treated with glucocorticoids.2, 6-8 These effects are amplified by in-
creased energy intake due to obsession with food, and impaired physical activity.3, 9 In 
the long term these metabolic side effects may contribute to the higher risk of childhood 
leukemia survivors to develop metabolic syndrome (MetS).10-13 A recent study in 784 
ALL survivors showed that 34% has MetS, as defined by National Cholesterol Education 
Program – Adult Treatment Panel III criteria.14 
Although prednisolone also affects metabolism, dexamethasone has a more intense 
toxicity profile2, 15 with major metabolic changes in a short period of time, like increased 
energy intake and insulin resistance. Dexamethasone-induced insulin resistance after 
only five days has been reported in a study in 18 pediatric ALL patients.6 So, even in short 
term dexamethasone seems to affect components of the MetS. The latter is defined for 
children ≥10 years as abdominal obesity, plus any two or more of the clinical features: 
hyperglycemia, hypertriglyceridemia, reduced HDL cholesterol, hypertension.16 Esben-
shade et al. longitudinally followed 34 patients for one year of maintenance therapy, 
containing prednisone or dexamethasone, and documented a worsening of weight gain, 
insulin resistance, and leptin levels in the same children with ALL over the year.17 This 
emphasizes the impact of acute glucocorticoid-induced metabolic toxicity on the long 
term. Since dexamethasone pulses are administered in the Dutch Childhood Oncology 
Group (DCOG) ALL protocols for one and a half year during maintenance, it is conceiv-
able that risk factors for developing MetS accumulate. However, prospective studies on 
direct dexamethasone-induced effects on all components of the MetS in a substantial 
cohort of pediatric ALL patients are lacking. In addition no information is available on 
the role of dexamethasone pharmacokinetics on the occurrence of MetS. We therefore 
in the context of a randomized controlled trial, studied prospectively the acute effects of 
dexamethasone on all components of the MetS, and the role of dexamethasone serum 
levels in a subset of patients. 
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mATeRiALS And meThodS
Patients
The study protocol was approved by the Ethics committee of the Erasmus MC and the 
local ethics committees at each participating center (MEC-2012-155/ EudraCT 2011-
003815-46): University Medical Center Utrecht, Academic Medical Center Amsterdam, 
VU Medical Center, University of Groningen Medical Center. In accordance with national 
regulations, parents and legal guardians of patients provided written informed consent; 
patients 12-16 years of age also provided their own written informed consent. Fifty chil-
dren with ALL, aged 3 to 16 years, who completed the placebo course of the multicenter 
randomized controlled trial, the Dexadays study (NTR3280)18, were included for the 
present study. 
Patients received dexamethasone pulses during maintenance phase according to 
DCOG ALL protocols in fi ve pediatric oncology departments in the Netherlands. Since 
asparaginase treatment may cause hypoalbuminemia, is associated with greater plasma 
exposure to dexamethasone19, infl uences glucose metabolism, and may cause changes 
in lipid levels, we included children only after discontinuation of the asparaginase phase. 
Patients underwent an oral dexamethasone course of 5 days (6 mg/m2/day) with addi-
tion of a placebo (10 mg/m2/day)(containing 0.26 g/mL sorbitol 70% solution) during 
the Dexadays study. (Figure 1) Dexamethasone was given together with vincristine 2 
 
Incomplete 
measurements (7) 
50 patients of Dexadagenstudy 
screened for eligiblity 
50 patients eligible and included 
for prospective study 
50 patients 
analyzed for 
weigth 
42 patients 
analyzed for 
glucose 
40 patients 
analyzed for 
insulin 
42 patients 
analyzed for 
lipid profile 
43 patients 
analyzed for  
blood 
pressure 
-not serum samples at both time points (3) 
-inadeaquate fasting (5) 
-inadequate insulin measurement (2) 
 
Figure 1. Consort fl owchart.
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mg/m2 on day 1, 6-mercaptopurine 50 mg/m2 daily and methotrexate 30 mg/m2 weekly. 
Our primary outcome was metabolic toxicity during one dexamethasone course. 
Anthropometry
Height (m), weight (SDS), waist circumference (cm) were measured before start of 
dexamethasone (T1) at baseline. Blood pressure (mmHg) was measured at T1 and at the 
morning of the fifth dexamethasone course day (T2). Blood pressure was measured with 
the subject in sitting position after one hour of rest on the right arm with the Dinamap® 
Procare. Cut-off values for these anthropometric parameters corrected for age and sex 
were obtained from Cole et al.20 (BMI: adiposity, obesity), the reference values of the 
National High Blood Pressure Education Program Working Group21 (hypertension), 
and Fredriks et al.22 (waist circumference: >1.3 SD = abdominal adiposity, >2.3 SD = 
abdominal obesity). Blood pressure was expressed as SDS adjusted for height and sex.23 
Hypertension was defined as blood pressure (either systolic or diastolic) above the 95th 
percentile for age and sex.21
Laboratory measurements
At T1 and T2, following overnight fasting, peripheral blood samples were obtained for 
measurement of insulin, glucose, total cholesterol, high-density lipoprotein–cholesterol 
(HDL), low-density lipoprotein-cholesterol (LDL) and triglycerides levels. Laboratory ref-
erence values of the department of Clinical Chemistry of the Erasmus Medical Center24 
and International Diabetes Federation16 were used. The serum samples were stored at 
-80oC until the analyses were performed after inclusion was completed. Serum samples 
were determined in one and the same laboratory using an enzymatic in vitro assay 
(Roche Diagnostics, Mannheim, Germany).18 
Impaired fasting glucose (IFG) was defined as fasting glucose ≥5.6 mmol/L and <7.0 
mmol/L using the ADA criteria.25 Hyperinsulinemia was defined as a fasting insulin value: 
pre-pubertal (≥15 mU/L), mid-puberty (≥30 mU/L), and post-pubertal (≥20 mU/L).26 
Insulin resistance index was calculated by homeostasis model assessment of insulin 
resistance (HOMA-IR), which is calculated by the following formula: fasting glucose 
(mmol/L)* fasting insulin (mU/L) / 22.5.27 A cut-off of HOMA-IR ≥ 3.4 is chosen because 
of its predictive value for impaired glucose tolerance and diabetes mellitus, based on 
literature.28-33 We also performed the analysis using the cut-off value HOMA-IR>4.39 for 
insulin resistance as used by Chow et al.6, in order to be able to compare our data. 
Metabolic syndrome (MetS) was defined by the International Diabetes Federation 
(IDF) criteria for children ≥10 years of age with abdominal obesity (waist circumference 
≥90 percentile), plus any two of more of the clinical features: hyperglycemia, hypertri-
glyceridemia, reduced HDL cholesterol, hypertension.16 
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Pharmacokinetics
Dexamethasone trough levels were measured at T2 (Pharmacology department, Aca-
demic Medical Center, Amsterdam). Due to the lack of available plasma samples, serum 
samples that were obtained on the morning of the fifth day before dexamethasone 
administration were used. No correction for measurement in serum was needed, since 
serum levels did not significantly differ from plasma levels. (P=0.37) The exact time of 
oral dexamethasone intake the night before was retrieved from patient diaries. 
Statistics
The effect of dexamethasone was assessed by comparing the results at baseline and 
at day 5 by a Paired T-test (for normally distributed measures) or a Wilcoxon Signed 
Rank test. Pearson’s coefficient and Spearman’s coefficient described the correlation (r) 
between values. All analyses were performed using SPSS, version 21.
ReSuLTS
Baseline characteristics
For this study, 50 patients were included (46% males). (Figure1) Serum samples for 
laboratory measurements were missing for 3 patients. The median age was 6.0 years 
(interquartile range (IQR): 4.0, 10.3). Adiposity, based on BMI, was present in 7% of these 
patients at diagnosis and increased to a prevalence of 19% at study baseline. Abdominal 
adiposity, based on waist circumference >1.3 SD, was found in 48% of the patients at 
study baseline. Obesity, defined by BMI, was not present at diagnosis and increased to 
a prevalence of 4% at study baseline. Abdominal obesity, based on waist circumference 
>2.3 SD, was present in 10% at study baseline. Weight SDS (r=0.44, P=0.00) and the pres-
ence of a high BMI (r=0.35, P=0.02) were linearly correlated with age. 
Glucose metabolism 
Serum samples of five patients were excluded for measurement because of inadequate 
fasting. Median fasting glucose levels (N=42) significantly increased (Figure 2) after four 
days of dexamethasone treatment (median: 0.40 mmol/L (IQR: -0.20, 1.03), P=0.00). An 
impaired fasting glucose (IFG)27 was not observed at baseline. Two patients (5%) had an 
IFG after four days of dexamethasone (P=0.32). (Table 1) Higher fasting glucose levels on 
dexamethasone were correlated with older age (r=0.49, P=0.03). There was no influence 
of gender or week of maintenance phase on glucose levels. 
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Figure 2. Fasting glucose values at baseline and after four full days of dexamethasone treatment. N=42.
Table 1. Increase (=delta) in fasting lipid, glucose and insulin levels (median (Inter Quartile Range)) or the in-
crease in occurrence of high glucose, HDL, LDL, total cholesterol, triglycerides or insulin levels during 4 days of 
dexamethasone treatment. The effect of dexamethasone on lipids and glucose (N=42) was tested with a Paired 
T-test. The effect of dexamethasone on insulin (N=40) and HOMA-IR (N=39) was tested with a Wilcoxon Signed 
Rank test.
delta P-value
Glucose (mmol/L) Median (IQR) 0.40 (-0.20, 1.03) 0.00
hyperglycemia N(%) 2 (5) 0.96
hdL Median (IQR) 0.11 (-0.06, 0.32) 0.00
Low hdL N(%) -2 (5)
0.01
high hdL N(%) 6 (14)
LdL Median (IQR) 0.24 (-0.03, 0.52) 0.00
high LdL N(%) 4 (9) 0.00
Total cholesterol Median (IQR) 0.40 ( 0.08, 0.73) 0.00
high Total cholesterol N(%) 7 (16) 0.01
Triglycerides Median (IQR) 0.17 (-0.08, 0.47) 0.04
hypertriglyceridemia N(%) 7 (17) 0.09
insulin (pmol/L) Median (IQR) 173.75 (129.28, 334.55) 0.00
high insulin N(%) 32 (80) 0.00
homA-iR Median (IQR) 4.66 (3.50, 10.27) 0.00
insulin resistance homA-iR > 4.39  N(%) 26 (67) 0.00
insulin resistance homA-iR>3.4 N(%) 30 (77) 0.00
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Laboratory measurements
The median insulin level at baseline (N=40) was 25.2 pmol/L (IQR: 14.4, 73.4). Four 
days of dexamethasone significantly increased insulin levels (median: 173.75 pmol/L 
(IQR: 129.28, 334.55), P=0.00). (Figure 3) Hyperinsulinemia was present in 4 patients 
(10%) at baseline and in 36 patients (90%) after 4 days of dexamethasone treatment 
(P=0.00). HOMA-IR (N=39) values significantly increased over the course (median: 4.66 
(IQR: 3.50, 10.27), P=0.00, Figure 4). The prevalence of insulin resistance (HOMA-IR >3.4) 
significantly increased on dexamethasone (8% at T1 vs 85% at T2, P=0.00). Even using 
the cut-off values as defined by Chow et al. (HOMA-IR > 4.39)6, insulin resistance signifi-
cantly increased from 5% to 72% (P=0.00). Hyperinsulinemia at baseline was correlated 
with older age (r=0.41, P=0.01). None of the patients received insulin therapy during the 
dexamethasone course. Gender and the week of maintenance phase did not influence 
insulin resistance.
Lipid profile
Serum samples of five patients were excluded for measurement because of inadequate 
fasting. Dexamethasone increased median fasting blood levels (N=42) of HDL (median 
delta: 0.11 mmol/L (IQR: -0.06, 0.32), P=0.00), LDL (median: 0.24 mmol/L (IQR: -0.03, 
0.52), P=0.00), total cholesterol (median: 0.40 mmol/L (IQR: 0.08, 0.73), P=0.00), and 
triglycerides (median: 0.17 mmol/L (IQR: -0.08, 0.47), P=0.04) (Figure 5, Table 1). High 
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Figure 3. Insulin (pmol/L) values at baseline and after four full days of dexamethasone treatment. N=40.
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HDL, high LDL, high total cholesterol and hypertriglyceridemia were already present in 
respectively 12%, 17%, 10% and 24% at baseline, and increased to 26%, 26%, 26% and 
41% respectively by dexamethasone. (Table 1) Dexamethasone administration did not 
result in a decrease of HDL. Gender, age, and the week of maintenance phase did not 
influence dexamethasone-induced change in lipid serum levels.
Blood pressure
Blood pressure was successfully measured for 43 patients. Dexamethasone treatment 
significantly increased diastolic blood pressure SDS (median: 0.33 (IQR: -0.24, 0.94), 
P<0.01), and systolic blood pressure SDS (median: 0.58 (IQR: -0.61, 1.24), P<0.05). (Figure 
6) Increase in diastolic blood pressure was inversely related with age (r=-0.43, P<0.01). 
Hypertension (either diastolic or systolic), defined as a blood pressure >95th percentile 
corrected for age and sex, was present in 25% of the patients at baseline and increased 
to 39% by dexamethasone (P=0.14), and was inversely correlated with age (r=-0.36, 
P=0.02). Systolic hypertension at baseline was inversely correlated with age (r=-0.33, 
P=0.03) and more often diastolic hypertension on dexamethasone (r=-0.47, P=0.00).
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Figure 4. HOMA-IR values at baseline and after four full days of dexamethasone treatment. N=39. 
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Figure 6. Dexamethasone-induced changes in diastolic and systolic blood pressure (BP) SDS values by four full 
days of dexamethasone treatment: value day 5 - value baseline. N=43. Median is depicted. A positive score re-
flects an increased SDS level by dexamethasone. *= P<0.05. **= P<0.01.
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Figure 5. Dexamethasone-induced changes in HDL, LDL, total cholesterol, triglyceride and glucose values 
(mmol/L) in four days: value day 5 - value baseline. The effect of dexamethasone was tested with a Paired T-
test. *= P<0.05. **= P<0.01. Median is depicted for each laboratory measurement. A positive score reflects an 
increased level by dexamethasone.
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components of the metS
The International Diabetes Federation defines MetS for children >10 years as abdominal 
obesity, plus any of the two or more of the following clinical features: hyperglycemia, hy-
pertriglyceridemia, reduced HDL cholesterol, and hypertension. Abdominal obesity was 
observed in 7 patients (15%, 3 males) after four days of dexamethasone. These children 
had a median age of 9.0 years (IQR: 3.0, 12.0). Three of these patients had developed 
hyperglycemia, hypertension, or hypertriglyceridemia, which are all components of the 
MetS, during four days of dexamethasone treatment. (Table 2) The oldest patient was 12 
years of age and had a fasting glucose of ≥5.6 mmol/L and a high systolic blood pressure 
at T2. The other patients were younger than 10 years of age and developed a high blood 
pressure and hypertriglyceridemia within four days of dexamethasone treatment. 
components of the metabolic syndrome
Table 2. The presence of components of the metabolic syndrome (MetS) at baseline and after four full days of 
dexamethasone treatment.
Abdominal 
obesity
hyper-
glycemia
hyper-
triglyceridemia
Reduced 
hdL 
cholesterol
hypertension Abdominal 
obesity + ≥2 metS 
components
Baseline 
N (%)
5 (10) 0 (0) 10 (24) 2 (5) 11 (25) 0 (0)
on dex 
N (%)
7 (15) 2 (5) 17 (41) 0 (0) 17 (39) 3 (7)
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Figure 7. Dexamethasone trough serum levels were positively correlated with glucose levels after four days of 
dexamethasone treatment (r=0.63, P<0.01). The correlation was described with a Spearman’s coefficient.
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Pharmacokinetics
Dexamethasone trough levels after four days of treatment were available for 24 patients, 
and showed a median of 3.97 ug/L (IQR: 1.45 – 11.81 ug/L). Trough levels were not cor-
related with age, gender or week of maintenance phase. Dexamethasone trough levels 
were not significantly different between patients with or without abdominal obesity 
(P=0.17).
Dexamethasone trough levels were positively correlated with increase in glucose 
levels during dexamethasone (r=0.66, P<0.01) and with glucose levels after four days of 
dexamethasone treatment (r=0.63, P<0.01, Figure 7). Dexamethasone trough levels did 
not directly influence insulin resistance, lipid serum levels and blood pressures. 
diScuSSion
This is the first study that investigated the acute effects of four days of dexamethasone 
on all components of the metabolic syndrome in a substantial cohort of ALL patients. We 
showed that one dexamethasone course significantly increased glucose, lipids, insulin 
resistance, and blood pressure, thereby influencing three out of six factors of the MetS; 
hyperglycemia, hypertriglyceridemia, and hypertension. In contrast to Chow et al6, who 
reported an 35.5% increase (N=31) in insulin resistance during one steroid (prednisone/
dexamethasone) course, we found an dexamethasone-specific increase in insulin resis-
tance of 67% in a larger population. This could be explained by the fact that 6 mg/m2 
dexamethasone is more potent than 40 mg/m2 prednisolone.1 The amount of preceding 
dexamethasone courses did not influence the metabolic effects of dexamethasone.
On the short-term these metabolic toxicities could have various consequences. High 
glucose levels and insulin resistance could induce microvascular problems34, impair-
ment of the innate immune system35, and changes in hemostatic responses36. The short-
term metabolic toxicities are not age-dependent. Our results emphasize, that although 
MetS criteria are lacking for children <10 years, young ALL patients are not spared from 
metabolic toxicity.
On the long term the accumulating disguised metabolic toxicity of dexamethasone 
courses during one and a half year of maintenance therapy may contribute to the high 
incidence of MetS in childhood leukemia survivors14, 37, thereby increasing the risk for 
diabetes and cardiovascular diseases.14 Esbenshade et al. has already reported an in-
crease in insulin resistance of 49% during one year of maintenance phase containing 
glucocorticoids 17, which supports the hypothesis of accumulating metabolic toxicity. 
In comparison, inadequate glucose control in pediatric diabetes mellitus type I has also 
shown to lead to more long-term complications.38
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Dexamethasone-induced weight gain, which is influenced by changes in eating be-
havior3, may contribute to the cardiovascular and diabetic risk.3, 17 The prevalence of adi-
posity (based on BMI) in our population increased substantially from 7% at diagnosis to 
19% at study baseline. The study baseline prevalence of adiposity was higher compared 
to the Dutch general population (13%)39, but the incidence of obesity was comparable 
(4%)39. However, abdominal adiposity and abdominal obesity, both common steroid-
related side effects40, were significantly more common in our population. Measuring 
waist circumference may therefore be valuable, since steroids induce redistribution of 
fat to the upper trunk and face, with a loss of fat in the extremities.40 
One of the other metabolic side effects is dexamethasone-induced hypertension, 
which has been described before during 28 days of prednisone-based induction therapy 
in 45% of ALL patients7, of whom 27% was receiving anti-hypertensive drugs. Hyperten-
sion was seen in 6% of our ALL patients during five days of dexamethasone therapy, and 
no anti-hypertensive drugs were administered. Dexamethasone-induced hypertension 
could involve the promotion of inotropic and vasoconstrictive effects on the cardiovas-
cular system.40 Our study confirmed earlier findings7 that young age seems to be a risk 
factor for developing steroid-induced hypertension. 
Dexamethasone trough levels were positively correlated with glucose levels. These 
increased glucose levels could be caused by inhibition of glucose uptake in peripheral 
tissues and stimulation of hepatic gluconeogenesis by direct effect on hepatic gene 
expression.40 We presumed more metabolic parameters to be associated with dexa-
methasone clearance, since toxicity has been associated high with dexamethasone 
levels before.41 The lack of influence of dexamethasone levels on lipids and insulin could 
be caused by insufficient power and short-term exposure. Also, the pathophysiologic 
mechanism of metabolic side effects, although it has not been completely unraveled, 
may be side effect specific40, 42, which could possibly explain the differences between 
metabolic side effects. The results underscore the need for a large pharmacokinetic 
study with long follow-up to further investigate the association between dexametha-
sone drug levels and metabolic toxicity. Since dexamethasone trough levels varied 
widely between patients, individualized dosing of dexamethasone in children with ALL 
may be the next step.
To conclude, we demonstrated the serious disguised metabolic toxicities of dexametha-
sone on short-term. We showed that even four days of dexamethasone in ALL patients 
significantly affects components of the MetS, and that dexamethasone levels influence 
glucose metabolism. Our findings do not have direct clinical consequences, but they 
could form the basis for further studies on personalized treatment, for example indi-
vidualized dexamethasone dosing, targeted therapy with selective glucocorticoids43, 
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and programs supporting a healthy diet and physical activity. This is important because 
the accumulating disguised metabolic toxicities, together with the weight gain during 
dexamethasone treatment, may contribute to the higher prevalence of MetS and cardio-
vascular risk childhood leukemia survivors.
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Predicting the neuropsychological side 
effects of dexamethasone in pediatric acute 
lymphoblastic leukemia.
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ABSTRAcT
Dexamethasone, an effective treatment of acute lymphoblastic leukemia (ALL), can 
induce serious neuropsychological side effects that vary between patients. We hypoth-
esized that these side effects are influenced by glucocorticoid sensitivity at the tissue 
level. We therefore prospectively studied whether we could predict these side effects 
by a very low dose dexamethasone suppression test (DST) or by dexamethasone trough 
levels. Fifty ALL patients (3-16 years) were included during the maintenance phase 
(with dexamethasone courses) of the Dutch ALL protocol. As marker of glucocorticoid 
sensitivity, the salivary very low dose DST was used. A post-dexamethasone cortisol 
<2.0nmol/L was considered a hypersensitive response. Neuropsychological endpoints 
consisted of questionnaires on psychosocial and sleeping problems before and during 
a dexamethasone course. Dexamethasone trough levels were measured during dexa-
methasone (6mg/m2) treatment.
Patients with a hypersensitive response (N=13, 26%) had more dexamethasone-
induced behavioral problems (median delta: 1.0 (inter quartile range: 0.0,2.0) versus 0.0 
(-0.5,1.0), P=0.01), sleeping problems (4.5 (0.0, 13.5) versus 0.0 (-3.0, 2.0), P=0.03), and/
or somnolence (3.0 (1.0, 6.0) versus 1.0 (-0.5, 2.5), P<0.05). The positive predictive value 
of the DST for psychosocial problems and sleeping problems was 50% and 30% respec-
tively. Dexamethasone levels were not associated with neuropsychological side effects. 
We conclude that the very low dose DST and dexamethasone trough levels could not 
accurately predict neuropsychological side effects. However, patients with glucocorti-
coid hypersensitivity experienced significantly more dexamethasone-induced depres-
sive symptoms. Future studies should further elucidate the glucocorticoid sensitivity 
dependent mechanisms by which neuropsychological side effects are influenced.
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inTRoducTion
Dexamethasone is an important drug in the treatment of pediatric acute lymphoblastic 
leukemia (ALL)1-3 but its side effects can have major impact on the quality of life of 
patients.4-6 Currently, in the Dutch ALL protocols, during the maintenance period of 
1.5 years, medium risk ALL patients receive five-day standard-dose dexamethasone 
courses in three weekly cycles. The reported occurrence of neuropsychological side 
effects in pediatric ALL patients shows extreme variation of 5-75%.4, 7, 8 In a minority 
of cases side effects are even so severe that dexamethasone treatment is switched to 
prednisolone or discontinued, accepting a negative impact on outcome. Identification 
of patients at risk for developing neuropsychological side effects would enable indi-
vidualized treatment to potentially reduce dexamethasone-induced side effects. Still, 
tools to predict neuropsychological side effects during dexamethasone treatment are 
lacking. Corticosteroids bind to mineralocorticoid receptors (MRs) and glucocorticoid 
receptors (GRs). The imbalance in activation of the GR and the MR in the brain caused by 
exogenous glucocorticoids, seem to play an important role in the pathophysiology of 
neuropsychological side effects.9 Previous studies indicate that although the sensitivity 
of the GR seems variable between individuals, the intra-person sensitivity is stable. This 
is supported by the observation that baseline plasma cortisol concentrations, which are 
regulated by a GR dependent feedback system, vary widely between normal subjects 
but show high intra-individual stability.10 
The sensitivity of the hypothalamic-pituitary-adrenal (HPA) axis feedback system to 
glucocorticoids can be measured by a very low dose dexamethasone (0.25 mg) suppres-
sion test (DST). In population-based studies, subjects with the highest baseline cortisol 
concentrations also had the highest post-DST concentrations. It further seems that 
within an individual, there is a specific set point for HPA-activity, which can be defined 
before as well as after a low dose of dexamethasone. A dose of 0.25 mg dexamethasone, 
which results in a subtotal suppression of cortisol levels, does not influence this set point. 
In the 0.25 mg DST, post-DST cortisol levels show a Gaussian distribution, where the 
subjects in the extremes are relatively hypersensitive or resistant to glucocorticoids.10 
Apart from differences in glucocorticoid sensitivity, pharmacokinetic variation is also 
a possible explanation for inter-individual differences in dexamethasone related side 
effects. Dexamethasone clearance in pediatric ALL patients is inversely related to age.11 
Poor dexamethasone clearance has been reported in ALL patients with osteonecrosis, 
another serious side effect of dexamethasone.11 Whether dexamethasone pharmaco-
kinetics also influences the occurrence of neuropsychological side effects, is unknown.
The aim of our study was to assess the predictive value of the very low dose dexa-
methasone suppression test, and to assess whether dexamethasone serum levels influ-
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ence the occurrence of neuropsychological side effects of dexamethasone in pediatric 
ALL. 
mATeRiAL And meThodS
Participants
Children with ALL, aged 3 to 16 years, who were enrolled in the multicenter randomized 
controlled trial, the Dexadays study (NTR3280)12, were included. Patients were receiving 
5-day dexamethasone pulses (6mg/m2/day) every three weeks during maintenance 
phase according to the DCOG ALL protocols. Measurements were performed before and 
during the placebo course of the Dexadays study. The study protocol was approved by 
the local ethics committee (MEC-2012-155/EudraCT 2011-003815-46). The study was 
performed in accordance with the Declaration of Helsinki and followed the principles 
of good clinical practice.
cortisol measurement
A very low dose salivary dexamethasone suppression test (DST) was performed in the 
week before a dexamethasone pulse. Salivary cortisol measurement is a reliable and 
minimally invasive method to assess the active, unbound form of cortisol.13 Patients were 
requested to collect saliva samples at home using Salivette sampling devices (Sarstedt, 
Rommelsdorf, Germany) after obtaining informed consent and detailed oral and written 
instructions concerning the saliva sampling. Saliva samples were collected in the week 
before a dexamethasone course. Five saliva samples were collected during two consecu-
tive days at five time points (Table 1); that is, immediately at awakening (T1= baseline), 
at noon (T2), around 4pm (T3), in the evening at bedtime (T4), and immediately at awak-
ening on the consecutive day post-DST (T5). After obtaining the T4 sample on the first 
day, a very low dose of dexamethasone (0.25 mg/ 1.73 m²) was taken orally. Parents were 
asked to write down the exact times and date of saliva collections. Furthermore, patients 
were instructed not to brush their teeth and not to eat 15 minutes before saliva sampling 
to avoid contamination of saliva with blood caused by micro-injuries to the oral cavity. 
Besides these restrictions, the children were otherwise free to follow their normal daily 
routines on the sampling day. Parents were instructed to store saliva samples in the 
fridge until finalizing the collection of five samples. Thereafter, the samples were sent 
to the Diagnostic Endocrinology Laboratory of the Erasmus MC, where samples were 
stored in the freezer at -80oC until completion of the inclusion. Cortisol concentrations 
were measured using a commercial immunoassay with chemiluminescence detection 
(CLIA; IBL Hamburg, Hamburg, Germany). The lower limit of detection was 0.4 nmol/
liter. (Erasmus MC. 2015) Data were screened for quality of cortisol measurements. Saliva 
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samples were used to measure the cortisol day curve (T1-4), and the post-DST cortisol 
level (T5). HPA-axis response was assessed by comparing morning cortisol levels at T1 
and T5 (cortisol suppression). 
Severe cortisol suppression was defined as a post-DST cortisol level (T5) < 2.0 nmol/L. 
This cut-off was chosen based on the Guidelines for Cushing Syndrome of the Endocrine 
Society, which recommends a cut-off for suppression of the post-DST (1mg DST) serum 
cortisol levels of <50 nmol/L to achieve high sensitivity rates.14 Since serum cortisol 
levels are almost 27 times higher than salivary cortisol levels15, we chose 2.0 nmol/L as 
cut-off level for severe post-DST cortisol suppression.
dexamethasone pharmacokinetics
Dexamethasone trough levels were measured after four full days of 6 mg/m2 dexa-
methasone (Pharmacology department, Academic Medical Center, Amsterdam). For this 
purpose, serum samples, obtained on the morning of the fifth day before dexametha-
sone administration, were used. Time of intake of dexamethasone the night before was 
retrieved from patient diaries. 
neuropsychological side effects
Psychosocial problems were measured by the parent-reported Strengths and Difficul-
ties Questionnaire in Dutch (SDQ-Dut)16 before start of dexamethasone and at day 5 
of the dexamethasone course (placebo). A delta-score (i.e., the difference between two 
scores) was calculated by subtracting the score on treatment day 1 score from the score 
on treatment day 5.12 The SDQ-Dut has 25 items on 5 subscales: Emotional symptoms, 
Conduct problems, Hyperactivity and inattention, Peer relationship problems, and 
Prosocial behavior. The cumulative score was calculated by combining the 5 subscales 
minus the Prosocial behavior scale into a “Total difficulties” score. The Impact score is 
an extra subscore and reflects the impact of the difficulties on the child’s life. Clinically 
relevant psychosocial problems were defined as a delta SDQ Total difficulties score ≥5.12
Sleeping problems were assessed by the Sleep Disturbance Scale for Children (SDSC)17 
on the first day and fifth day of the dexamethasone course. It has a Total score and covers 
dexamethasone Suppression Test scheme
Table 1. Schedule of the very low dose dexamethasone suppression test. 
Time Day 1 Day 2
Morning Fasting saliva sample (T1) Fasting saliva sample (T5)
Noon Saliva sample (T2)
Afternoon Saliva sample (T3)
Evening Saliva sample (T4)
Evening Very lose dose dexamethasone
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6 most common sleep disorders of childhood: Disorders of Initiating and Maintaining 
Sleep (DIMS), Sleep Breathing Disorders (SBD), Disorders of Arousal (DA), Sleep Wake 
Transition Disorders (SWTD), Disorders of Excessive Somnolence (DES), and Sleep Hy-
perhydrosis (SHY).12 Clinically relevant sleeping problems were defined as a delta SDSC 
Total score ≥7.12
Statistics
Cortisol values were compared by a Paired T-test (for normally distributed measures) 
or a Wilcoxon Signed Rank test. Spearman’s coefficient described the correlation (r) 
between cortisol values and SDQ scores and SDSC scores. All analyses were performed 
using SPSS, version 21. To evaluate the predictive value of the salivary low dose DST 
on dexamethasone-related neuropsychological side effects, a nested analysis was per-
formed. The positive predictive value (PPV) is defined as (number of true positives based 
on SDQ≥5 or SDSC≥7) / (number of positives based on DST< 2.0 nmol/L). The probability 
value used to identify significance was P<0.05.
ReSuLTS
Baseline characteristics
48 of 50 patients, included in the Dexadays study12, completed the salivary very low 
dose suppression test. Patients (46% male) had a median age of 6.0 years (IQR: 4.0, 10.3). 
The post-DST cortisol level (T5) was missing in one patient. 
Adrenal function during maintenance
Baseline cortisol levels (T1) varied widely between patients (median 11.2 nmol/L, (IQR: 
7.3, 15.4)). Seventeen patients (35%) revealed a morning cortisol level below the refer-
ence range (<9.0 nmol/L)18 at T1. Cortisol levels decreased during the day (T2: median 
3.6 (IQR: 2.7, 5.4), T3: median 2.6 (IQR: 1.7, 3.5), T4: median 1.4 (IQR: 0.8, 1.9), reflecting the 
physiological circadian rhythm of cortisol production. (Figure 1) Morning cortisol levels 
were higher in female patients (female: median 13.1 nmol/L (IQR: 10.8, 17.5) versus male: 
median 8.2 nmol/L (IQR: 6.0, 12.0), P=0.01). No associations of morning cortisol levels 
(T1) with age, week of maintenance phase or dexamethasone trough level were found. 
The post-DST cortisol levels (T5) were significantly lower than baseline cortisol levels 
at T1, respectively median 3.7 (IQR: 1.9, 7.9) versus median: 11.2 (IQR: 7.3, 15.4) (P<0.001), 
and varied widely between patients. The median suppression in cortisol level following 
a very low dose of dexamethasone was 6.8 nmol/L (IQR: -9.6, -1.0). Seven patients (15%) 
did not show dexamethasone-induced cortisol suppression. Dexamethasone-induced 
cortisol suppression was not associated with gender, age nor with week of maintenance.
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hPA-axis reactivity as predictor of neuropsychological side effects
Increased cortisol suppression was correlated with a higher parent-reported SDQ Impact 
score after four days of dexamethasone treatment (r=-0.43, P<0.01). In the total group 
more pronounced cortisol suppression (defined as a post-dexamethasone cortisol level 
<9.0 nmol/L) was associated with more increase in Conduct problems (r=-0.35, P=0.02) 
and Impact of difficulties (r=-0.34, P=0.03) during dexamethasone treatment. Cortisol 
suppression was not associated with an increase in other SDQ subscales or SDSC sub-
scales on dexamethasone. 
Thirteen patients (26%) had severely suppressed post-DST cortisol levels below 2.0 
nmol/L14. These children had significantly more dexamethasone-induced Conduct prob-
lems than patients with a post-DST cortisol level ≥2.0 nmol/L (median delta SDQ Con-
duct problems: 1.0 (IQR: 0.0, 2.0) vs 0.0 (IQR: -0.5, 1.0), P=0.01). (Figure 2) The difference 
in delta score between two groups was 0.7 standard deviation score on the Conduct 
problems subscale. This subset of patients also had significantly more dexamethasone-
induced Total sleeping problems (delta 4.5 (IQR: 0.0, 13.5) vs 0.0 (IQR: -3.0, 2.0), P=0.03), 
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Figure 1. Cortisol day curve. The median cortisol level (nmol/L) of the study population at four time points is 
depicted.
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Figure 2. Patients with a post-DST cortisol <2.0 nmol/L (N=13) had significantly more dexamethasone-induced 
Conduct problems. Medians are depicted.
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Figure 3. Patients with a post-DST cortisol <2.0 nmol/L (N=13) had significantly more dexamethasone-induced 
Total sleeping problems.
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and Disorders of Excessive Somnolence (delta 3.0 (IQR: 1.0, 6.0) vs 1.0 (IQR: -0.5, 2.5), 
P<0.05). (Figure 3-4)
Although patients with glucocorticoid hypersensitivity had more dexamethasone-
induced conduct problems and sleeping problems, the positive predictive value of 
severe cortisol suppression for clinically relevant psychosocial problems during dexa-
methasone was only 50%. In addition, the positive predictive value of severe cortisol 
suppression for clinically relevant sleeping problems during dexamethasone was 30%.
dexamethasone levels as predictor of side effects
Serum dexamethasone trough levels after 4 days of dexamethasone were available for 
24 patients (50%), and showed a median of 3.97 ug/L (IQR: 1.45, 11.81). Dexamethasone 
trough levels were not associated with dexamethasone-induced neuropsychological 
problems, based on the SDQ-Dut for psychosocial problems and the SDSC for sleeping 
disorders.
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Figure 4. Patients with a post-DST cortisol <2.0 nmol/L (N=13) had significantly more dexamethasone-induced 
Disorders of Excessive Somnolence.
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diScuSSion
This is the first study that investigated predictors of dexamethasone-induced neuropsy-
chological side effects in pediatric ALL patients. The very low dose DST did not accu-
rately predict neuropsychological problems of dexamethasone treatment. In addition, 
dexamethasone trough levels did not influence neuropsychological side effects. 
Interestingly, however, patients being most sensitive to dexamethasone-induced 
suppression of the HPA-axis, experienced significantly more behavioral and sleeping 
problems including excessive somnolence during dexamethasone treatment. These 
results suggest, that children with relative glucocorticoid hypersensitivity are at risk 
for depressive symptoms during dexamethasone courses, as these specific behavioral 
problems have been identified as possible symptom of childhood depression. It has to 
be acknowledged, that the clinical presentation of depression in children differs from 
adults, in particular the occurrence of behavioral problems and less anhedonia. Because 
of these differences between children and adults, recently, the diagnosis of ‘Disruptive 
Mood Dysregulation Disorder’ was added to the Diagnostic and Statistical Manual of 
Mental Disorders 5th edition. This disorder is characterized by severe and recurrent 
temper outbursts with irritable or angry mood in between.19 Interestingly, these types 
of behavioral problems overlap with the ones that have been frequently reported in 
pediatric ALL patients on dexamethasone.20, 21 
The mechanism behind the increased neuropsychological side effects in the patients 
with hypersensitive responses is unknown. We could not find evidence that this was me-
diated by differences in pharmacokinetics, as dexamethasone levels were not associated 
with the extent of cortisol suppression. However, the influence of variable dexametha-
sone pharmacokinetics on neuropsychological side effects should be analyzed more 
extensively in a larger cohort by including the peak levels and the area under the curve.
Although the DST is not suitable as diagnostic tool for neuropsychological side effects, 
it may give us more insight in the pathophysiologic mechanism behind these side ef-
fects. Up until now it is not clear what determines the inter-individual differences in 
glucocorticoid sensitivity in response to the very low dose DST. There might be a role 
for genetic variation. Glucocorticoid receptor (GR) polymorphisms are associated with 
both glucocorticoid sensitivity and depression.22 For example, harboring the ER22/23EK 
polymorphism (rs6189 and rs6190, G>A, located on exon 2) seems to protect against 
the development of adrenal insufficiency after high-dose glucocorticoid therapy23, and 
seems to be relatively protective for cognitive effects of increased HPA axis activity.24 
Homozygous carriers of the BclI polymorphism (rs41423247, C>G, located 646 nucleo-
tides downstream from exon 2) have an increased susceptibility for prolonged adrenal 
insufficiency23, and have an increased risk for a major depression.24 We did not analyze 
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genetic variants in our study because large numbers of participants would be needed 
to power the study.
The very low dose DST, which is an easy test with a low burden for patients, may be 
used during maintenance phase to identify patients with prolonged adrenal insuf-
ficiency. One third of our study population had a suppressed morning cortisol in a week 
of maintenance phase preceding a dexamethasone course. These children are at risk 
for life-threatening complications and may benefit from glucocorticoid replacement 
therapy during periods of serious stress in the first weeks after cessation of dexametha-
sone.25 Adrenal insufficiency after glucocorticoid therapy in pediatric ALL patients has 
been previously reported.25, 26 The impaired stress response and an inadequate host 
defense against infections in these patients, remains a cause of morbidity and death 
in childhood.27 Hypoglycemia after prolonged fasting, which can be a sign of adrenal 
insufficiency, has been reported as a common adverse effect of maintenance therapy28, 
and could potentially affect behavior, mood and sleep. However, fasting glucose levels 
during dexamethasone were not associated with neuropsychological side effects nor 
with the magnitude of HPA-axis suppression in our study population.
In conclusion, the very low dose DST was not an appropriate diagnostic tool to predict 
dexamethasone-induced neuropsychological problems in pediatric ALL patients. In ad-
dition, dexamethasone trough levels did not influence neuropsychological side effects. 
The association with a hypersensitive response in the very low dose DST and behavioral 
and sleeping problems, however, points to a possible role of genetic variation in the 
occurrence of neuropsychological side effects that vary widely between patients. 
Therefore, future studies on genetic variation are needed to better understand the 
pathophysiology of these toxicities, which is important for developing interventions to 
improve the quality of life during the maintenance phase.5
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ABSTRAcT
Background: Large prospective studies on dexamethasone-induced changes in eat-
ing behavior, energy and nutrient intake are lacking in pediatric acute lymphoblastic 
leukemia (ALL). 
objectives: We prospectively studied eating behavior, energy and nutrient intake dur-
ing dexamethasone administration in children with ALL.
methods: Parents of ALL patients (3-16 years) completed a dietary diary for their child 
during 4 days of dexamethasone (6mg/m2) administration. Energy intake and nutrient 
intake (energy percentiles=E%) were assessed and compared with the recommended 
intake. The Dutch Eating Behavior Questionnaire for Children was completed before 
start and after 4 days of dexamethasone by patients 7-12 years of age. 
Results: Energy intake per day (kcal) (N=44) increased significantly during dexametha-
sone (median day 1: 1103 (717-1572) versus day 4: 1482 (1176-1822), P<0.01), including 
an increase of total protein, fat, saturated fat, carbohydrate, and sodium intake. Intake 
of saturated fat (median day 4: 12E%) and salt (median day 4: 1.9 gram/day) exceeded 
the healthy range for age and gender. With respect to eating behavior, dexamethasone 
significantly decreased restrained eating (P=0.04).
conclusions: Four days of dexamethasone treatment significantly increased energy 
intake, including excessive saturated fat and salt intake, and changed eating behavior 
in children with ALL. Nutritional and behavioral interventions during dexamethasone 
treatment are recommended to stimulate a healthy lifestyle.
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inTRoducTion
Dexamethasone is an important component of the treatment of pediatric acute lym-
phoblastic leukemia (ALL), but it is notorious for its induction of various serious side 
effects. One of the frequently reported side effects in ALL patients is increased appetite.1 
Even short-term glucocorticoid treatment can lead to an altered eating behavior and 
increased food intake.2, 3 Still, prospective studies addressing this issue are scarce and 
include a limited number of patients.1, 2 
The effect of glucocorticoids on appetite is not completely unraveled, but seems to be 
regulated through changes in gene expression of the hypothalamic appetite regulatory 
peptides, for example neuropeptide Y.4 In the acute situation, for example by a stressor, 
cortisol inhibits food intake5, 6 and liberates energy from resources to meet the energetic 
demands for fight or flight. In contrast, chronic glucocorticoid administration stimulates 
feeding.7, 8
Animal studies have reported that glucocorticoids increase salt appetite by increase 
of water and sodium excretion9, but the changes in food preference of ALL patients 
during dexamethasone treatment have not been studied. Dexamethasone-induced 
psychosocial stress10 could contribute to unhealthy food preferences in ALL patients.11 
Psychosocial stress has been previously associated with food responsiveness, which 
reflects eating in response to external food-related cues like the sight, smell, and taste of 
food, regardless of their physical need for food.12 
Repetitive five-day dexamethasone courses are administered for at least 1,5 years 
during maintenance therapy of the most recent and ongoing Dutch Childhood Oncol-
ogy Group (DCOG) ALL protocols. The suggested concomitant increased energy intake 
during dexamethasone courses together with impaired physical activity1, 2 and other 
dexamethasone-induced metabolic toxicities13-16 may contribute to the higher risk of 
developing obesity and metabolic syndrome in ALL survivors with consequent cardio-
vascular sequelae.17, 18 A recent study in 784 American ALL survivors showed that 34% 
has metabolic syndrome.19 
To date, neither dexamethasone-induced changes in nutrient or energy intake have 
been studied in a large cohort of ALL patients in the period of dexamethasone-pulses. 
Therefore, we investigated this in a prospective study. Secondly, we describe the under-
lying emotional, external and restraint eating behavior, leading to the excessive dietary 
pattern during dexamethasone treatment.
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Patients
Children with ALL, aged 3 to 16 years, receiving oral dexamethasone (6 mg/m2/day) 
in the maintenance phase of Dutch Childhood Oncology Group ALL protocols were 
included. In this phase of treatment dexamethasone was administered together with 
vincristine 2 mg/m2 on day 1, 6-mercaptopurine 50 mg/m2 daily and methotrexate 30 
mg/m2 weekly. The part of the maintenance phase in which the study was performed, 
contained 19 five-day dexamethasone courses. The children were studied prospectively 
during one of these dexamethasone courses. The median start of the study was in the 
fourth dexamethasone course after stop of asparaginase. During the first four days of 
this dexamethasone course, energy and nutrient intake were registered. Eating behavior 
was measured at baseline before start of dexamethasone (T1) and at day 5 of treatment 
(T2). Weight (kg) and height (cm) were measured at T1 to calculate body mass index 
(BMI). Cut-off values for BMI corrected for age and sex were obtained from Cole et al.20
energy and nutrient intake 
Energy intake was calculated over four consecutive days during the dexamethasone 
pulse, from parent-reported dietary diaries. Parent-reported diaries during four days 
of dexamethasone treatment were complete for 44 patients. Food intake data were 
converted to energy intake (kcal) using the database of the chemical composition of 
foods in the Netherlands21. Macronutrients and sodium intake was assessed from the 
dietary diaries by a dietician. Data on the recommended daily allowance of macronu-
trients (protein: ≤25 energy percentiles (E%), carbohydrate: 40-70 E%, total fat: ≤40 E%, 
saturated fat: ≤10 E%) and sodium (3 years: 1.0 g/day, 4-8 years: 1.2 g/day, 8-16 years: 1.5 
g/day) were retrieved from the Health Council of the Netherlands, and were corrected 
for age and gender.22 The resting metabolic rate was calculated with use of the Schofield 
equation with correction for age and gender.23 To calculate the individual energy re-
quirements based on Schofield we used the following formula: energy needs = (resting 
metabolic rate x (activity factor (1.1)+ disease factor (1.2) -1) x growth factor (1)) / energy 
absorption coefficient (0.98).24
eating behavior
Data on eating behavior were collected at baseline before start of dexamethasone (T1), 
and at day 5 (T2) of the dexamethasone course. Eating behavior was measured by the 
Dutch Eating Behavior Questionnaire for Children (DEBQ-C: 7-12 years)25. The DEBQ-C 
has three subscales: Restrained Eating (7 items), Emotional Eating (7 items), and External 
Eating (6 items); a higher score on each subscale reflects the more pronounced presence 
of problems. The Restrained Eating scale assesses both intentions to restrict food intake 
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and actual behavioral restrained (dieting). Emotional eating means eating in response 
to emotional arousal states such as fear, anger of anxiety. External eating means eating 
in response to external food cues such as sight and smell of food. The DEBQ-C has been 
validated for use in children 7-12 years of age and was therefore completed only by all 
17 patients 7-12 years of age. 
Statistics
The recommended daily allowance and the intake were compared with a Wilcoxon 
Signed Rank test. Spearman’s coefficient described the correlation r between energy 
and nutrient intake and gender, age and baseline BMI. The effect of dexamethasone on 
eating behavior was assessed comparing the results at T1 and T2 by a Wilcoxon Signed 
Rank test. The differences in eating behavior for different categories, based on DEBQ-C 
subscores, were compared with a Mann-Whitney U test. All analyses were performed 
using SPSS, version 21.
ReSuLTS
Baseline characteristics
Fifty patients were included (46% males). Their median age was 6.0 years (interquartile 
range (IQR): 4.0, 10.0). The median week of maintenance phase was week 37 (IQR: 31, 
48). The median weight SDS was 0.13 (IQR: -0.48, 0.86). At T1, based on BMI20, 19% was 
overweight, and obesity was present in 4% of the patients. In the general population of 
the Netherlands the prevalence of overweight and obesity in this age category are 14% 
and 2% respectively.26
energy intake 
The dietary diaries were completed for 44 children. At day 1 the median energy intake 
was 19% lower than the recommended energy intake. The median energy intake per day 
increased significantly during four days of dexamethasone (median day 1: 1103 (IQR: 
717, 1572) versus median day 4: 1482 (IQR: 1176, 1822), P<0.01) (Figure 1), resulting in a 
median energy intake at day 4 that was 9% higher than the recommend energy intake 
(median: 1306 (IQR: 1139, 1707). The number of patients with an energy intake above 
their individual energy requirements increased from day 1 to day 4 (11 patients (25%) 
to 28 patients (64%) respectively). Increased energy intake at day 4 was associated with 
younger age (r=-0.41, P<0.01). The energy intake (corrected for age and gender) was 
independent of the week of maintenance phase, in which the patient participated.
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macronutrient and sodium intake
The protein intake (median day 1: 1.3 g/kg (IQR: 0.9, 2.3) versus day 4: 2.1 g/kg (IQR: 1.5, 
2.8), P<0.01), total fat intake (median day 1: 1.5 g/kg (IQR: 0.8, 2.4) versus day 4: 2.4 g/kg 
(IQR: 1.3, 3.0), P<0.01), saturated fat intake (median day 1: 0.6 g/kg (IQR: 0.3, 1.0) versus 
day 4: 1.0 g/kg (IQR: 0.5, 1.3), P<0.01), and carbohydrate intake (median day 1: 4.9 g/kg 
(IQR: 3.5, 8.8) versus day 4: 8.9 g/kg (IQR: 5.2, 11.9), P<0.01) increased significantly during 
the dexamethasone course. (Figure 1) In addition sodium intake increased significantly 
during the course (median day 1: 1.4 g/day (IQR: 1.0, 2.0) versus day 4: 1.9 g/day (IQR: 1.2, 
2.9), P<0.01). (Figure 2) 
The energy percentages of protein, fat, and carbohydrate contributing to daily intake 
(E%), did not significantly change. (Figure 1) The median E% of protein (14%), fat (32%), 
and carbohydrate (54%) intake were within normal limits of the recommended daily 
allowance. In contrast, the median E% of saturated fat (median day 1 and day 4: 12 E%) 
was constantly higher than recommended, and medium sodium intake exceeded the 
healthy limit during the dexamethasone pulse (median day 4: 1.9 g/day). Nutrient intake 
(E%) was independent of age and gender.
eating Behavior 
The DEBQ was completed for 17 children in the age of 7-12 years. Before start of dexa-
methasone Emotional Eating and Restrained Eating were decreased in ALL patients 
compared to the norm of the Dutch population (Z-score <0.00). Patients showed more 
Energy intake during dexamethasone
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Figure 1. Median total energy intake (kcal) per treatment day, divided in the median contributing percentiles 
proteins, fat, and carbohydrates during four days of dexamethasone. The median norm intake (based on the 
formula: energy needs = (resting metabolic rate x (activity factor (1.1)+ diseas e factor (1.2) -1) x growth factor 
(1)) / energy absorption coefficient (0.98)24) is depicted with the dashed grey line.
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External Eating at baseline compared to healthy peers. Four days of dexamethasone 
treatment significantly decreased Restrained Eating (median: -0.43 (IQR: -0.82, 0.95) vs 
-0.62 (IQR: -1.06, -0.16), P=0.04), but did not change Emotional Eating (median: -0.74 
(IQR: -0.74, 0.05) vs -0.74 (IQR: -0.74, 0.70), P=0.24), and External Eating (median: 0.60 
(IQR: -0.24, 1.34) vs 0.59 (IQR: -0.04, 1.14), P=0.25) in the 17 patients. (Figure 3)
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Figure 2. Sodium intake during during four days of dexamethasone treatment. The median norm sodium in-
take is depicted with the dashed line. 
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Figure 3. Eating behavior based on Dutch Eating Behavior Questionnaire (DEBQ) on day 1 and day 5 of dexa-
methasone treatment. Subscores: emotional eating, external eating and restraint eating.
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As expected, patients with an increase on the subscale of Emotional Eating >0.5 (Z-
score) during dexamethasone treatment had a higher total energy intake in four days 
than patients with less increase of Emotional Eating respectively (median: 6866 kcal (IQR: 
6020, 9115) versus 5106 kcal (IQR: 4063, 6198), P<0.04) and a higher fat intake in four 
days (median: 9.3 g/kg.d, IQR: 6.2, 11.1 versus median: 5.7 g/kg.d, IQR: 3.6, 7.9, P=0.04).
diScuSSion
Energy intake increased significantly during the four consecutive days of dexamethasone 
treatment, along significantly increased total protein, fat, saturated fat, carbohydrate, 
and sodium intake. Interestingly, whereas the relative contribution of protein, fat, and 
carbohydrate to energy intake remained within normal limits, intake of saturated fat 
and salt exceeded the healthy range during dexamethasone treatment. With respect to 
eating behavior, dexamethasone significantly decreased restrained eating. 
The preferences for salty and fatty foods seem to go along, since the total excess so-
dium intake was associated with the total saturated fat intake during the four days of 
dexamethasone. Since most of the Dutch pediatric ALL patients receive dexamethasone 
courses for at least 1.5 years, a dexamethasone-induced high fat and salty diet have to 
be watched for as they may contribute to the high incidence of metabolic syndrome and 
consequent cardiovascular sequelae in ALL survivors.18 Nowadays, it is unknown whether 
there is a causal relationship between the unhealthy diet during dexamethasone pulses 
and metabolic syndrome in ALL survivors. A recent study in the USA, showed that one 
third of ALL survivors had the metabolic syndrome.19 Increased fat consumption and an 
overall unhealthy diet, which is also reported in long-term ALL survivors27, has already 
shown to be associated with the occurrence of metabolic syndrome.28 For example, high 
salt intake could lead to hypertension, but is also a potential risk factor for obesity.29 The 
higher incidence of adiposity and obesity in the study population can also contribute to 
the increased risk of metabolic syndrome, since Weiss et al. reported that the prevalence 
of metabolic syndrome among obese children is high and increases with worsening 
obesity.30 
With respect to eating behavior, our results are limited to the children aged 7 to 12 years. 
Patients under the age of 7, however, also had unhealthy diets during dexamethasone 
treatment, and a higher energy intake than recommended was associated with younger 
age. It would therefore be very interesting to study their emotional and external eating 
behavior, which may be higher due to less developed impulse control in this age group. 
Future studies should include these young children. 
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Although the long-term effects of high saturated fat and salt intake, together with the 
increased energy intake and extreme eating behavior during dexamethasone pulses 
need to be studied more extensively, the unhealthy eating pattern in children treated 
for ALL with dexamethasone, emphasizes the need for nutritional and behavioral 
interventions. Behavioral problems, accompanying dexamethasone treatment10 could 
hinder nutritional interventions, underscoring the need for developmental- and age-
directed coaching by professionals, closely involving the parents. Early intervention may 
prevent an unhealthy lifestyle post-treatment, which could increase the risk for obesity, 
metabolic syndrome, and consequent cardiovascular sequelae later in life.
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General discussion
Hydrocortisone as novel intervention for neuropsychological side effects
The results of this thesis suggest that hydrocortisone addition provides a valuable 
intervention for clinically relevant dexamethasone-induced psychosocial and sleeping 
problems in children with acute lymphoblastic leukemia (ALL). It is the first randomized 
controlled clinical trial that investigated whether an intervention with a low patient 
burden can be used to reduce dexamethasone-induced side effects. The beneficial ef-
fects for a subset of 38% of patients are promising, since current therapeutic options 
for dexamethasone-induced neuropsychological side effects are scarce, and limited to 
antidepressants and antipsychotics with accompanying side effects.1-4 
Before introducing this novel intervention to clinical practice, however, the beneficial 
effects need validation in larger cohorts of patients with clinically relevant neuropsy-
chological side effects. Primarily, because a quarter of the participating patients in our 
study did not experience neuropsychological side effects, which could have influenced 
the results of the total study population. Regression to the mean may have influenced 
results. 
Till validation, pediatric oncologists may incidentally consider the use of hydrocorti-
sone for ALL patients with extreme dexamethasone-induced behavioral, depressive or 
psychotic symptoms, and start hydrocortisone administration in a circadian rhythm dur-
ing dexamethasone treatment. In such patients the severity of the side effects outweigh 
the lack of validation, especially because physiological dosages of hydrocortisone have 
a low patient burden and has proven to be safe at the short-term. Further research is 
needed for long-term safety, although theoretically no issues are foreseen. 
Prediction of patients that may benefit from this novel intervention
Before implementation of hydrocortisone as intervention for neuropsychological side 
effects in clinical practice, it may be important to select those that will benefit from hy-
drocortisone addition. Upfront we hypothesized that these side effects were influenced 
by glucocorticoid sensitivity at the tissue level and may therefore be predicted by a very 
low-dose dexamethasone suppression test. Our results, however, showed that, although 
a correlation was found between glucocorticoid hypersensitivity and more behavioral 
and sleeping problems during dexamethasone, this test is not an adequate tool to select 
individual patients. (Chapter 6) 
Since prediction tools are lacking, patients with clinically relevant neuropsychological 
side effects need to be selected during dexamethasone treatment. The parent-reported 
Strengths and Difficulties Questionnaire (SDQ) and the parent-reported Sleep Distur-
bance Scale for Children (SDSC) have already shown to be valuable tools to quantify psy-
chosocial problems and sleeping problems during dexamethasone treatment. (Chapter 
4) These parent-reported questionnaires are validated for patients 3-16 years of age 
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and are not time-consuming and convenient in a clinical setting, in contrast to other 
behavioral questionnaires, like the Child Behavior Checklist5 and the Behavior Rating 
Inventory of Executive Function6. The Behavior Rating Inventory of Executive Function 
has a parent-reported short version with 24 items7, but is validated for children from 5 
years of age. 
Based on recent changes in the Diagnostic and Statistical Manual of Mental Disorders, 
behavioral problems in children could be a symptom of depression, which has a differ-
ent clinical presentation in childhood, compared to depression in adults. Since behav-
ioral problems are frequently seen during dexamethasone treatment, a questionnaire 
focusing on depressive symptoms, for example the 13-item Short Mood and Feelings 
Questionnaire could also be valuable to select patients with neuropsychological prob-
lems. This brief instrument evaluates depressive symptoms of children aged 8-18 years, 
and may be a short and practical option in a follow-up study.8 
A limitation of our study was the use of the self-reported Dutch Eating Behavior Ques-
tionnaire, which was only validated for children aged 7-12 years.9 As a consequence data 
on eating behavior in younger children are missing. An increased energy intake during 
dexamethasone, however, was associated with younger age, so a parent-reported ques-
tionnaire on eating behavior, like the Child Eating Behavior Questionnaire10, for these 
younger children would be valuable. 
Since we aim to improve quality of life by diminishing neuropsychological side ef-
fects, questionnaires assessing the quality of life like the 23-item Pediatric Quality of Life 
Inventory 4.011 could be valuable too. This questionnaire takes only five minutes to be 
completed and has a parent- and child-reported version.11
Potential improvements of the intervention 
Hydrocortisone was administered in our patients in order to restore the balance between 
the mineralocorticoid receptor (MR) and the glucocorticoid receptor (GR) activity in the 
brain that become under activated and over activated respectively by dexamethasone 
treatment.12-14 Besides, the circadian rhythm of administration is essential to mimic the 
natural daily pattern of cortisol secretion12, which was emphasized by different studies. 
In patients with adrenal insufficiency, who lack cortisol secretion15, cortisol replacement 
without mimicking the physiological circadian rhythm leads to more side effects, like 
hyperglycemia and insulin resistance, by overexposure during parts of the day when 
cortisol exposure is normally low16. Low nighttime cortisol levels in patients with Ad-
dison’s disease might also lead to sleep disturbances.17 Normal nighttime cortisol levels 
in healthy humans are necessary for normal rapid eye movement sleep regulation.18 Al-
though our treatment schedule replenishes cortisol in a three times daily dosing sched-
ule, the normal biorhythm of cortisol is not completely mimicked. Based on a study of 
Mah et al.19, this treatment renders some patients overtreated immediately after oral ad-
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ministration and undertreated within a few hours. During nighttime and early morning, 
the glucocorticoid levels during oral hydrocortisone treatment are undetectable, which 
is in contrast with the rise seen in healthy individuals20. This may be an explanation for 
the fact that not all neuropsychological side effects completely disappeared in our study 
patients. Recently, continuous subcutaneous infusion of hydrocortisone in Addison’s 
disease successfully mimicked the physiological cortisol rhythm.21 Although this might 
be a treatment option in ALL patients who poorly respond to oral hydrocortisone, it has 
a higher patient burden and it is not practical during the maintenance phase, in which 
patients visit the outpatient clinic only once a week.
Our current treatment schedule with hydrocortisone administration should remain 
limited to the period in which dexamethasone courses are administered. Glucocorticoid 
administration during off-dexamethasone weeks could lead to adrenal insufficiency22, 
an impaired stress response, and an inadequate host defense against infections23, al-
though this is only expected when using supra-physiological doses.
Future research may focus on developing more selective glucocorticoids to prevent 
unwanted side effects. As an example, recently, a selective GR modulator, C108297, was 
developed with suppressive effects of stress-induced hypothalamus-pituitary-adrenals 
(HPA) axis activity in the brain in rats, but without unwanted stimulatory effects on 
amygdala CRF that would affect systemic basal cortisol levels.24 The development of 
selective glucocorticoids that have anti-leukemic effects but lack side effects, would 
overcome the burden of the dexamethasone-induced neuropsychological toxicities.
Interventions for acute metabolic side effects and changes in eating behavior
Beside its neuropsychological side effects, dexamethasone acutely influenced com-
ponents of the metabolic syndrome, and induced an increased energy intake in more 
than 60% of patients. Hydrocortisone had no beneficial effect on these side effects, 
presumably because the pathophysiologic mechanisms of various side effects differ.25-27 
For example, dexamethasone-induced hypertension may be due to inotropic and 
vasoconstrictive effects of glucocorticoids on the cardiovascular system25, while hyper-
glycemia is induced by inhibition of glucose uptake in peripheral tissues and stimulation 
of hepatic gluconeogenesis.25 Dexamethasone-induced weight gain is influenced by 
changes in eating behavior28, changes in physical activity29, and GR-dependent stimula-
tion of adipocyte hypertrophy30 especially in visceral adipose tissue31. We found that 
high dexamethasone trough levels were associated with high glucose levels (Chapter 
5), which emphasizes the need for more extensive pharmacokinetic studies that include 
measurement of peak levels and area under the curve, in a large cohort of ALL patients.
The acute effects of dexamethasone on components of the metabolic syndrome (hy-
perglycemia, hypertriglyceridemia, and hypertension), the increased energy intake32, 33, 
and the unhealthy eating pattern (especially more saturated fat and salt), could contrib-
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ute multifactorially to the high incidence of metabolic syndrome in childhood leukemia 
survivors.34, 35 Therefore, interventions should not only focus on short-term toxicities, but 
also on the long-term risk of diabetes and cardiovascular diseases.35 Such interventions 
could include nutritional and behavioral interventions during maintenance treatment, 
to stimulate a healthy lifestyle. Physical activity, which is decreased during dexametha-
sone treatment in children with ALL29, should be encouraged. It may, however, be hard 
for patients to adhere to exercise programs during two years of ALL treatment.36 The 
inter-patient variability in eating behavior during dexamethasone suggests that, inter-
ventions may be most effective if designed in a patient-tailored way. Behavioral prob-
lems, accompanying dexamethasone treatment could hinder nutritional interventions, 
underscoring the need of developmental- and age-directed coaching by professionals. 
Parents should be closely involved in these interventions. 
Variability in neuropsychological side effects
Dexamethasone-induced neuropsychological side effects vary widely between patients. 
38% of the study population developed clinically relevant psychosocial and sleeping 
problems. Future studies should explore whether genetic variation plays a role in this 
wide variety. Studies in other patient groups have found gene variants in the MR and 
GR that may contribute to inter-individual differences. For example, MR haplotype 2 
is associated with dispositional optimism and protects against depression.37 Also, GR 
polymorphisms have been shown to be associated with both glucocorticoid sensitiv-
ity and depression.38 For example, harboring the ER22/23EK polymorphism seems to 
protect against the development of adrenal insufficiency after high-dose glucocorticoid 
therapy39, and seems to be relatively protective for cognitive effects of increased HPA 
axis activity.40 Carriers of a homozygous Bcl1 polymorphism have an increased sus-
ceptibility for prolonged adrenal insufficiency39, and have an increased risk for a major 
depression.40
Differences in sensitivity of the HPA-axis feedback to glucocorticoids may also contrib-
ute to the inter-patient variability in neuropsychological side effects. This thesis showed 
that patients with a hypersensitive HPA-axis feedback experienced more behavioral 
problems, total sleeping problems, and excessive somnolence during dexamethasone 
treatment. (Chapter 6) The mechanism behind the increased problems in patients with 
hypersensitive responses is unknown. 
Patients with HPA-axis hypersensitivity showed some overlap in occurrence of 
clinically relevant neuropsychological side effects. However, a large group of patients 
with clinically relevant side effects did not have a hypersensitive response in the very 
low-dose DST (see Figure 1). Patients with glucocorticoid hypersensitivity may be more 
prone to develop MR:GR imbalance. 
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Future studies should focus on whether genetic variances that are known to play a 
role in depression and/or glucocorticoid sensitivity infl uence neuropsychological side 
eff ects in children with ALL. Genetic profi ling is unlikely to become an individual di-
agnostic tool for neuropsychological side eff ects, but it may give further insight in the 
pathophysiology. 
Pharmacokinetics did not seem to infl uence neuropsychological side eff ects. This was 
expected based on our hypothesis, as every patient will have a suppressed endogenous 
cortisol production during treatment with 6mg/m2 dexamethasone. Since we only mea-
sured trough levels, however, future pharmacokinetic studies need to investigate the 
infl uence of dexamethasone levels on neuropsychological side eff ects more extensively 
while including peak levels and area under the curve, and by analyzing a larger cohort. 
Children with higher dexamethasone levels, due to lower clearance, may for example 
become more hypersensitive to glucocorticoids.
Applicability of intervention for other patients
The current Dutch medium risk ALL treatment protocol includes 5-day dexamethasone 
courses of 6 mg/m2 in cycles of 3 weeks during at least one and a half year. Patients 
Pediatric ALL patients on 
dexamethasone 
N=1 
N=3 
N=3 
N=4 
N=1 
N=6 N=4 
N=48 
= glucocorticoid hypersensitivity 
= clinically relevant sleeping problems 
= clinically relevant psychosocial problems 
Figure 1. Overlap of patients with clinically relevant psychosocial side eff ects (SDQ), patients with clinically rel-
evant sleeping problems (SDSC), and patients with HPA-axis hypersensitivity.
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with rheumatic diseases or idiopathic thrombocytic purpura receive lower doses of 
dexamethasone. Neuropsychological side effects, however, have also been described 
during prednisone treatment in children with ALL.4, 41-43 These side effects do not seem 
to differ between dexamethasone and prednisone based on randomized controlled 
trials, but a prospective study of Pound et al.44 reported more behavioral side effects 
with dexamethasone. (Chapter 2) Based on our hypothesis the MR:GR balance would be 
less severely disturbed during prednisone treatment, because prednisolone, in contrast 
to dexamethasone, has some affinity for the MR beside its affinity for the GR. Predniso-
lone will bind the GR and MR with a ratio of 5:1, so there is still some MR activation.45 
Prednisone treatment, however, still leads to overactivation of the GR and suppression 
of circadian rhythm of the endogenous cortisol production, so patients receiving 
prednisone may also benefit from hydrocortisone. This hypothesis is supported by a 
case report of a patient with Cushing’s syndrome who needed synthetic glucocorticoid 
treatment after bilateral adrenalectomy, and developed severe psychotic symptoms 
that were unresponsive to psychotropic drugs as long as she was taking prednisone as 
replacement therapy. After she was switched to a regimen including cortisol that leads 
to more occupation of the MR, the psychopathology disappeared.46
The dexamethasone pulses during maintenance therapy in ALL are currently under 
discussion, but even if these pulses would be removed from maintenance therapy in 
future protocols, the novel intervention with hydrocortisone could still be valuable dur-
ing other phases of dexamethasone treatment in the ALL protocols.
In conclusion, pediatric ALL patients with clinically relevant neuropsychological prob-
lems during dexamethasone treatment seem to benefit from a physiological dose of 
hydrocortisone in a circadian rhythm. This novel therapeutic option, however, needs to 
be validated before introducing it into routine clinical practice. Apart from the SDQ and 
SDSC, short parent-reported depression-, eating behavior-, and quality of life question-
naires could be valuable for selection of patients that may benefit from this intervention. 
This selection is needed because not all patients experience clinically relevant neuropsy-
chological problems. Future pharmacogenomic and pharmacokinetic studies may give 
more insight in the variation in these side effects between patients. 
Apart from neuropsychological problems, dexamethasone treatment can lead to 
acute metabolic toxicity with a higher risk of the development of components of the 
metabolic syndrome. Therefore, patient-tailored nutritional and behavioral interven-
tions are needed to improve a healthy lifestyle during maintenance treatment.
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Summary
SummARY
Synthetic glucocorticoids, such as dexamethasone and prednisolone, are widely and 
successfully used as anti-leukemic agents1, 2, like in the Dutch treatment protocols for 
pediatric acute lymphoblastic leukemia (ALL). Dexamethasone is considered to be the 
preferred glucocorticoid based on its higher anti-leukemic activity3 and central nervous 
system penetration.1 However, the use of glucocorticoids, and especially dexametha-
sone, is notorious for various side effects, like metabolic and neuropsychological side 
effects.4-7 Neuropsychological side effects are experienced as the most detrimental to 
the quality of life by patients and their caregivers.8 Since most pediatric ALL patients 
receive dexamethasone courses during at least one and a half year, these side effects 
have a high impact on the daily life and development. To date, therapeutic interven-
tions to avoid dexamethasone-induced neuropsychological side effects are scarce, and 
limited to anti-depressive agents and antipsychotics.9-11 Therefore, there is a strong need 
for novel interventions to reduce these side effects. In this thesis we studied the efficacy 
of hydrocortisone as intervention for dexamethasone-induced neuropsychological side 
effects, based on the hypothesis that the neuropsychological side effects are due to cor-
tisol depletion of the mineralocorticoid receptor (MR) caused by dexamethasone. 16, 17
Our systematic review of literature showed no clinically meaningful differences between 
the effect of dexamethasone and prednisone on behavioral problems, mood disorders, 
cognitive effects, or sleeping problems5, 12-15(chapter 2).
We hypothesized that the neuropsychological side effects of dexamethasone in children 
with ALL are due to cortisol depletion of the MR caused by dexamethasone16, 17, which 
can be overcome by hydrocortisone addition. Before performing a clinical study, we 
needed to establish that MR activation with hydrocortisone did not interfere with the 
anti-leukemic activity of dexamethasone. Our in vitro study showed that hydrocortisone 
did not affect glucocorticoid sensitivity of ALL cell lines nor ALL cells primarily obtained 
from patients with different leukemic subtypes (chapter 3). We also identified a very 
low MR expression on ALL cells, and MR expression did not differ between glucocorti-
coid resistant and glucocorticoid sensitive patients’ cells. 
The findings of this preclinical study enabled the Dexadagen study, described in 
chapter 4, in which we investigated whether addition of a physiological dose of hydro-
cortisone to dexamethasone treatment decreases the neuropsychological side effects 
and metabolic side effects in children with ALL. In this multicenter double blind, ran-
domized controlled trial with a crossover design, 50 patients (3-16 years) were included 
during two consecutive courses of dexamethasone according to the Dutch Childhood 
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Oncology Group ALL protocols. The patients were randomly assigned to receive either 
hydrocortisone or placebo in a circadian rhythm (10 mg/m2/day) during the first or the 
second dexamethasone course. In the total group of patients, hydrocortisone addition 
had no significant effect on mood, behavior, sleep, cognition, and metabolism. However, 
a more detailed analysis in the nested group of 16 patients who had clinically relevant 
dexamethasone-induced psychosocial side effects revealed that the addition of hydro-
cortisone substantially reduced total psychosocial problems, emotional symptoms, be-
havioral problems, and the impact of the psychosocial problems in daily life. Moreover, 
in nine patients with clinically relevant sleep-related difficulties, hydrocortisone reduced 
overall sleeping problems, including initiating and maintaining sleep. In contrast, hydro-
cortisone addition had no effect on metabolic parameters. 
We also studied the direct effects of dexamethasone administration on all components 
of the metabolic syndrome (chapter 5). Four days of 6mg/m2 dexamethasone adminis-
tration significantly increased median fasting serum levels of HDL, LDL, total cholesterol, 
triglycerides, glucose and insulin. Insulin resistance (HOMA-IR>3.4) increased substan-
tially from 8% to 85%. Dexamethasone trough levels were positively correlated with 
high glucose levels after four days of dexamethasone, but not with other parameters. 
In addition, dexamethasone significantly increased diastolic and systolic blood pres-
sure. Altogether, we showed that even within four days of dexamethasone ALL patients 
developed an increment of components of the metabolic syndrome. 
Identification of patients at risk for developing neuropsychological side effects would 
enable individualized treatment to potentially reduce dexamethasone-induced side 
effects. We hypothesized that neuropsychological side effects may be influenced by 
glucocorticoid sensitivity at the tissue level, and determined whether we could predict 
these side effects by a very low dose dexamethasone suppression test (DST). We found 
that the subset of patients with a hypersensitive response (N=13, 26%) in the DST 
had more dexamethasone-induced behavioral problems, overall sleeping problems, 
including somnolence (chapter 6). The positive predictive value of the DST for psycho-
social problems and sleeping problems, however, was only 50% and 30% respectively. 
Therefore we concluded, that the very low dose DST is not of value as risk predictor for 
neuropsychological side effects. The association of behavioral problems and sleeping 
problems with a hypersensitive response in the very low dose DST, however, appoints to 
a possible role of genetic variation in the occurrence of neuropsychological side effects 
that vary widely between patients. 
Dexamethasone trough levels were not associated with neuropsychological side ef-
fects.
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Summary
Dexamethasone can also induce significant changes in eating behavior and energy 
intake. We prospectively studied eating behavior, energy and nutrient intake during 
dexamethasone administration (chapter 7). The energy intake per day was excessive 
during one dexamethasone course, and included an increase of energy intake, total 
protein, fat, saturated fat, carbohydrate, and sodium intake in more than 60% of the 
patients. Intake of saturated fat and salt exceeded the healthy range for age and gender. 
There was a high inter-patient variability in dexamethasone-induced eating behavior, 
but dexamethasone significantly decreased restrained eating in the total group. 
In conclusion, the results of this thesis suggest that hydrocortisone addition provides 
a valuable intervention for clinically relevant dexamethasone-induced psychosocial 
and sleeping problems in children with ALL. Before introducing this novel intervention 
to clinical practice, however, the beneficial effects need validation in larger cohorts of 
patients with clinically relevant psychosocial and sleeping problems.
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nedeRLAndSe SAmenvATTinG
Synthetische glucocorticoïden, zoals dexamethason en prednison, worden veel 
gebruikt in de behandeling van leukemie1, 2 en hebben een belangrijke plaats in het 
Nederlandse behandelprotocol van acute lymfatische leukemie (ALL). Dexamethason 
heeft de voorkeur vanwege zijn sterkere antileukemische werking3 en omdat het beter 
doordringt tot het centraal zenuwstelsel.1 Helaas kan het gebruik van deze glucocorti-
coïden tot verschillende bijwerkingen leiden, zoals metabole en neuropsychologische 
bijwerkingen.4-7 Volgens patiënten en hun ouders hebben neuropsychologische bijwer-
kingen de grootste impact op de kwaliteit van leven.8 Omdat kinderen in het huidige 
medium-risico ALL protocol gedurende tenminste anderhalf jaar dexamethason blok-
ken krijgen, kunnen deze bijwerkingen een grote impact op het dagelijks leven en de 
ontwikkeling van het kind hebben. Op dit moment zijn er weinig behandelopties voor 
neuropsychologische bijwerkingen van dexamethason en zijn ze beperkt tot antide-
pressiva en antipsychotica.9-11 Er is daarom behoefte aan nieuwe behandelingen om de 
neuropsychologische bijwerkingen te verminderen. In dit proefschrift hebben we de 
effectiviteit van hydrocortison bestudeerd als behandeling voor neuropsychologische 
bijwerkingen van dexamethason. De behandeling met hydrocortison is gebaseerd op 
de hypothese dat neuropsychologische bijwerkingen in kinderen met ALL verminderd 
kunnen worden door het tekort aan cortisol binding aan de mineralocorticoïd receptor 
(MR), veroorzaakt door dexamethason, op te heffen.16, 17
Onze systematische review van de literatuur liet geen klinisch relevante verschillen 
lieten zien tussen dexamethason en prednison op het gebied gedragsproblemen, stem-
mingswisselingen, cognitieve effecten of slaapproblemen5, 12-15 (hoofdstuk 2).
Wij veronderstelden dat neuropsychologische bijwerkingen van dexamethason worden 
veroorzaakt door het tekort aan cortisol binding aan de MR, die veroorzaakt wordt 
door dexamethason.16, 17 Tevens namen wij aan dat dit tekort aan cortisol binding kon 
worden opgelost door hydrocortison toevoeging.16, 17 Voordat dit in de kliniek getest 
kon worden, moesten we uitsluiten dat MR activatie met hydrocortison de antileuke-
mische werking van dexamethason niet beïnvloedt. Onze in vitro studie toonde aan dat 
hydrocortison de glucocorticoïd gevoeligheid van ALL cellijnen en ALL patiënten cellen 
van verschillende leukemie subtypen niet beïnvloedt (hoofdstuk 3). We vonden ook 
een erg lage MR expressie op leukemie cellen en de MR expressie verschilde niet tussen 
glucocorticoïd resistente en gevoelige patiënten cellen. 
De resultaten van de preklinische studie maakten de start van de Dexadagen studie 
mogelijk, welke beschreven is in hoofdstuk 4. Hierin onderzochten we of toevoeging 
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van een fysiologische dosis hydrocortison tijdens dexamethason behandeling de neu-
ropsychologische en metabole bijwerkingen in kinderen met ALL kon verminderen. In 
deze nationale, dubbelblinde, gerandomiseerde, placebo-gecontroleerde studie met 
een cross-over opzet werden 50 patiënten (3-16 jaar) behandeld met twee blokken 
dexamethason volgens het Nederlandse ALL protocol. De patiënten werden willekeurig 
ingedeeld om hydrocortison of placebo in een circadiaans ritme (10 mg/m2/dag) te krij-
gen tijdens het eerste of het tweede dexamethason blok. In de totale groep patiënten 
had hydrocortison geen effect op gedrag, stemming, slaap, cognitie en metabole bijwer-
kingen. Echter, in een meer gedetailleerde analyse in de subgroep van 16 patiënten die 
klinisch relevante psychosociale problemen door dexamethason ontwikkelden, bleek 
toevoeging van hydrocortison de psychosociale problemen, emotionele problemen, 
gedragsproblemen en de impact van de psychosociale problemen op het dagelijks 
leven, substantieel te verminderen. Daarnaast, verminderde hydrocortison in negen 
patiënten met klinisch relevante slaapproblemen, het totaal aantal slaapproblemen en 
de problemen met in slaap vallen en blijven. In tegenstelling tot het gunstige effect 
voor neuropsychologische problemen, had hydrocortison geen effect op metabole 
bijwerkingen. 
We onderzochten ook de acute effecten van dexamethason op alle componenten van 
het metabole syndroom. (hoofdstuk 5) Vier dagen behandeling met 6mg/m2 dexame-
thason leidde tot een significante stijging van nuchtere spiegels van HDL, LDL, totaal 
cholesterol, triglyceriden, glucose en insuline. Insuline resistentie (HOMA-IR>3.4) steeg 
substantieel van 8% naar 85%. Dexamethason dal spiegels bleken positief gecorreleerd 
aan hoge glucose waarden na vier dagen dexamethason. Daarnaast leidde dexame-
thason tot een significante stijging van de diastolische en systolische bloeddruk. Sa-
menvattend ontwikkelden kinderen met ALL tijdens slechts vier dagen dexamethason 
behandeling componenten van het metabool syndroom. 
Het herkennen van patiënten die kans hebben op het ontwikkelen van neuropsycholo-
gische bijwerkingen zou geïndividualiseerde behandeling mogelijk maken met als doel 
dexamethason-geïnduceerde bijwerkingen te verminderen. Wij veronderstelden dat 
deze bijwerkingen werden beïnvloed door glucocorticoïd gevoeligheid op weefselni-
veau en onderzochten of we de bijwerkingen konden voorspellen met een ‘zeer lage do-
sis’ dexamethason suppressie test (DST). Wij vonden dat de subgroep van patiënten met 
een hypersensitieve reactie in de DST (N=13, 26%) meer dexamethason-geïnduceerde 
gedragsproblemen, slaapproblemen en extreme vermoeidheid hadden (hoofdstuk 6). 
De positief voorspellende waarde van de DST voor psychosociale problemen en slaap-
problemen was echter slechts 50% en 30% respectievelijk. Daarom concludeerden wij 
dat de ‘zeer lage dosis’ DST geen adequate voorspeller is voor neuropsychologische 
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bijwerkingen. Het verband tussen gedrags- en slaapproblemen met een hypersensi-
tieve respons in de ‘zeer lage dosis’ DST, daarentegen, duidt op een mogelijke rol van 
genetische variatie in het optreden van neuropsychologische bijwerkingen, die variëren 
tussen patiënten. 
Dexamethason dal spiegels waren niet geassocieerd met neuropsychologische bij-
werkingen.
Dexamethason kan ook leiden tot significante veranderingen in eetgedrag en energie 
inname. We hebben prospectief het eetgedrag, de energie en nutriënten inname tijdens 
dexamethason behandeling bestudeerd (hoofdstuk 7). De energie inname per dag was 
excessief tijdens een dexamethason blok, en omvatte een toename van energie inname, 
totaal eiwit, totaal en verzadigd vet, koolhydraten, en zout inname in meer dan 60% 
van de patiënten. De inname van onverzadigd vet en zout overschreed de gezonde 
hoeveelheid voor leeftijd en geslacht. Er was een grote variabiliteit in eetgedrag tussen 
patiënten tijdens dexamethason behandeling, maar het lijngericht eten verminderde 
significant in de totale groep. 
Concluderend suggereren de resultaten van dit proefschrift dat hydrocortison toevoe-
ging een waardevolle behandeling is voor klinisch relevante psychosociale en slaappro-
blemen door dexamethason in kinderen met ALL. Voordat deze nieuwe behandeling in 
de kliniek kan worden toegepast, moeten de positieve effecten worden gevalideerd in 
een grotere groep patiënten met klinisch relevante psychosociale en slaapproblemen.
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List of abbreviations
LiST oF ABBReviATionS
AA auditory attention total correct
ANT Amsterdam neuropsychological tasks program
ALL acute lymphoblastic leukemia
BASC behavioral assessment system for children
BMI body mass index
BPAQ baecke physical activity questionnaire
BRIEF behavior rating inventory of executive function
CBCL child behavior checklist
CTCAE common terminology criteria for adverse events
DA disorders of arousal
DC design copying
DCPT design copying process total score
DES disorders of excessive somnolence
DCOG Dutch childhood oncology group
DEBQ-C Dutch eating behavior questionnaire for children
DIMS disorders of initiating and maintain sleep
DSM-5 diagnostic and statistical manual of mental disorders 5th edition
DST dexamethasone suppression test
GR glucocorticoid receptor
GRADE grading of recommendations assessment development and evaluation
HOMA-IR homeostasis model assessment insulin resistance index
HDL high-density lipoprotein–cholesterol
HPA hypothalamus-pituitary-adrenal
IDF international diabetes federation
IFG impaired fasting glucose
INE inhibition total errors
IQR interquartile range
LDL low-density lipoprotein-cholesterol
MDT memory for designs total score
MDDT memory for designs delayed total score
MetS metabolic syndrome
MR mineralocorticoid receptor
MRD minimal residual disease
MTT methyl-thiazol-tetrazolium salt drug cytotoxicity assay
NMFC narrative memory free and cued recall total score
NMRG narrative memory recognition total score
PCR polymerase chain reaction
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PedsQL pediatric quality of life inventory
PPV positive predictive value
PSI processing speed index
RCT randomized controlled trial
RDA recommended daily allowance
RS response set total correct
RT-qPCR quantitative real time polymerase chain reaction
SBQ sleep breathing disorders
SDQ strengths and difficulties questionnaire
SDS standard deviation score
SDSC sleep disturbance scale for children
SHY sleep hyperhidrosis
SWTD sleep-wake transition disorders
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Graag wil ik prof.dr. M.A. Grootenhuis, Prof.dr. E.F.C. van Rossum en Prof.dr. P.M. Hooger-
brugge hartelijk danken voor het beoordelen van mijn proefschrift en het plaatsnemen 
in de kleine promotiecommissie. Prof.dr. M.A. Grootenhuis, beste Martha, dank voor je 
enthousiaste inzet en hulp bij de opzet van de vervolgstudie. Prof.dr. C.M. Zwaan, beste 
Michel, het aanvankelijk plaatsnemen in de kleine commissie,  trial en data management. 
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Prof.dr. E.R. de Kloet, Dr. H.M. van Santen en Prof.dr. J.J. Cornelissen, wil ik hartelijk 
danken voor het plaatsnemen in de grote commissie.
Voor het eerst een klinische multicenter studie opzetten is niet eenvoudig. Datama-
nagers, research verpleegkundigen en andere lokale onderzoekers hebben mij hierbij 
enorm geholpen. Satianand, bedankt voor al je hulp bij het trialmanagement en veel 
plezier met je nieuwe baan. Inekee, dank voor de adviezen in de opzet fase van de stu-
die. Anneke en Ria, tijdens de afgelopen jaren heb ik veel van jullie mogen leren over het 
monitoren en het opzetten van een elektronische database. Jenny, Sandra, Kim, Martine 
en Pauline, jullie hulp bij de opzet en uitvoer van de Dexadagen studie in het AMC, 
VUmc, UMCG en UMCU was enorm waardevol. Zonder jullie had ik de studie niet zo snel 
kunnen afronden! Rianne Zaal, een geneesmiddelenstudie brengt veel extra’s met zich 
mee, daarbij was jouw begeleiding vanuit de apotheek onmisbaar.
Ik wil ook graag alle co-auteurs bedanken voor hun bijdrage. Dr. C. van den Bos, Dr. W.J.E. 
Tissing, Dr. M.A. Veening, Dr. M. Bierings, Prof.dr. C.M. Zwaan, beste Cor, Wim, Margreet, 
Marc en Michel, dank voor jullie inzet als lokale hoofdonderzoekers en jullie kritische blik 
op de studieresultaten. Prof.dr. M.L. den Boer, beste Monique, dank voor je begeleiding 
bij de opzet en de uitvoer van de preklinische studie.
Dr. F.K. Aarsen, beste Femke, jouw expertise bij de opzet van het neuropsychologische 
deel van de studie en de interpretatie van de resultaten was onmisbaar.
Saskia Pluijm, beste Saskia, jouw betrokkenheid bij de studie en statistische hulp 
heb ik zeer gewaardeerd. Helene Thygesen, beste Helene, dank voor je hulp bij de 
statistische analyse. Beste Marissa, dank je voor het controleren van de enorme PubMed 
search. Ingrid, als compleet groentje in het lab heb jij me aan de hand genomen en alles 
geduldig uitgelegd. Ik ben je enorm dankbaar voor al die tijd. Fijn dat je het zo naar je 
zin hebt in Boston.
Jacqueline, Anita, Jeanine en Jeanny, veel dank voor jullie hulp bij het regelen van af-
spraken, calls en handtekeningen. Lieve Jacqueline, door je vertrek naar de Bilt moesten 
we jouw gezelligheid op de 16e missen, maar het is mooi om te zien hoe jij je inzet voor 
het PMC! 
Collega-onderzoekers en SOV-genootjes, jullie hebben ervoor gezorgd dat mijn pro-
motie een fantastische tijd werd. Het sparren over het onderzoek, de gezellige borrels, 
skiweekenden, dinertjes en koffiepauzes waren onmisbaar.
Lieve SOV-bestuur vriendinnetjes, Dorian, Aukje, Marjolein, Gerbrich en Judith, verga-
deren onder het genot van Doppiootjes, geslaagde onderzoeksdagen vieren op het ter-
ras… ik heb een top tijd gehad! Lieve Dor, waarde lid van de skihelden sub en gezelligste 
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ZZV-maatje, dank voor jouw luisterend oor en je positiviteit! Gelukkig kom je dagelijks 
met de trein langs Amersfoort zodat we elkaar nog regelmatig kunnen zien. Lieve Auk, 
super fijn om met jou bestuur te doen. Altijd betrokken en vrolijk. Hopelijk worden we 
later weer collega’s! Lieve Marjolein, wat heb jij een enorme doorzettingskracht! Door 
jouw enthousiaste verhalen besloot ik me aan te melden voor het SOV-bestuur.
Lieve Manouk, ik zal jouw gezelligheid en eerlijkheid missen. De dagjes uit en dinertjes 
met de skihelden-sub zetten we gewoon door!
De wekelijkse QCAT was naast een researchmeeting ook een sociale aangelegenheid. 
Saskia, Wendy, Marjo, Manita, Karin, Marjolein, Wing, Andrica, Annelies, Eva, Ivana, Mark, 
Saskia Pluijm, Sebastiaan, Robin, Maite, Anne-Lotte en Natanja, wat is het gek om jullie 
niet meer dagelijks te zien en te spreken. Ik ga jullie missen. Het is heel waardevol om 
zo’n leuke en gezellige groep collega-onderzoekers te hebben. Ik sluit graag nog aan bij 
de borrels en etentjes! Marjo en Manita, jullie zijn toppers! Wat was ik blij dat ik bij jou op 
de kamer kwam, Marjo, altijd een luisterend oor en gezelligheid. 
Lieve Jasmijn, Ingrid en Sanne, dat het met zowel lab als klinische onderzoekers samen 
het nog leuker wordt, bewezen de gezamenlijke congressen.
Endo-meidengroep: Judith, Laura, Nienke, Renske, Manouk, Lin, Sinddie, Florentien en 
Stephany, door de verhuizing naar het Prinses Máxima Centrum kon ik er niet meer bij 
zijn op de dinsdagen, maar ik voel me nog steeds lid van de meidengroep en zal het lied 
niet snel meer vergeten. Dank voor alle leuke uitjes en jullie belangstelling.
Lieve Lisanne, ik mis onze Starbucks momentjes op de woensdagen. Wat was het 
ontzettend leuk om paranimf te zijn op jouw grote dag!
Beste oud-collega’s in het LangeLand; Jan, Edo, Femke, Jeanine, Lieke, Judith, Yvette, Re-
gina, Francine en Zahra, ik kijk met veel plezier terug op mijn tijd bij jullie. Dank dat jullie 
me lieten gaan om dit onderzoek te gaan doen. Lieve Zahr en Francien, jullie blijven de 
enige echte super-NPs.
Beste collega arts-assistenten en kinderartsen in het Meander MC, bedankt voor het 
fijne opleidingsklimaat en de prettige werksfeer. Ik heb het erg naar mijn zin bij jullie en 
voel me weer thuis in de kliniek.
Graag wil ik alle andere lieve vrienden en vriendinnen buiten het Sophia en PMC be-
danken voor de afleiding met alle niet-promotie gerelateerde activiteiten de afgelopen 
jaren. Dank dat jullie me in het verre Utrecht en nu nog verdere Amersfoort komen 
opzoeken! Heerlijke etentjes en drankjes, gezellige cordial-avonden, bijklets-momenten 
hier en daar, een fantastische Zuid Afrika road trip, oud-huisgenotenborrels en zeilweken 
betekenden heel veel voor mij en hebben de afgelopen jaren nog meer glans gegeven. 
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Lieve Helèn, dank voor de prachtige kanjer kralen die je speciaal voor de studie gemaakt 
hebt. 
Lieve schoonfamilie, Marianne, Rien, Merel, Dirk, Koen en Marjelijne, dank voor jullie 
interesse in mijn onderzoek en mij en uiteraard voor alle gezellige dagjes en weekendjes 
weg.
Lieve paranimfen, Saskia en Mirjam, wat ben ik blij dat jullie vandaag achter mij staan 
op deze grote dag. Lieve Sas, onze vriendschap begon vanaf het moment dat jij startte 
met je promotie. Ik kan me geen betere promotie-buddy bedenken dan jij! Samen hard 
lachen, ons hart luchten, de road trip door Canada, relativerende gesprekken tijdens de 
ups en downs van het promoveren en vooral heel veel Coca Cola, maakten de afgelopen 
jaren nog leuker. 
Lieve Mir, wat ben ik blij met een zus als jij! Je staat altijd voor me klaar en jouw nuch-
tere blik weet alles altijd weer te relativeren. Ik wens jou en Bas een hele mooie toekomst 
samen. Heel bijzonder dat jij vandaag mijn paranimf bent. 
Lieve papa en mama, dank voor jullie liefde, onvoorwaardelijke steun en interesse. Jullie 
heldere kijk op zaken heeft mij veel geleerd. Ook hebben jullie me altijd aangemoedigd 
al mijn dromen na te jagen en dat heeft me gebracht waar ik nu ben.
Allerliefste Bas, de laatste woorden hier zijn uiteraard voor jou. Dat ik jou heb leren 
kennen is het mooiste wat me is overkomen. Jouw levenslust, humor, relativeringsver-
mogen en niet te vergeten computer skills hebben mij door de stressvolle momenten 
van het promoveren heen geholpen. Ik hou oneindig veel van jou. Op naar nog heel veel 
mooie avonturen samen!


